Mobileye Releases First Quarter 2026 Results, Updates Full-Year Outlook, and Announces a $250 Million Share Repurchase Program

Mobileye Releases First Quarter 2026 Results, Updates Full-Year Outlook, and Announces a $250 Million Share Repurchase Program

  • Revenue of $558 million in the first quarter increased 27% year over year compared to Q1 2025. We are raising the midpoint of our full-year 2026 revenue guidance by 2% to reflect better-than-expected demand in the first quarter.

  • Diluted EPS (GAAP) was $(4.68) and Adjusted Diluted EPS (Non-GAAP) was $0.12 in the first quarter.

  • GAAP Operating Loss was impacted by a non-cash goodwill impairment of $3,788 million related to the goodwill asset on Mobileye’s balance sheet resulting from Intel’s acquisition of Mobileye in 2017.

  • Generated $75 million of operating cash flow in the first quarter of 2026. The acquisition of Mentee Robotics Ltd. (“Mentee Robotics”) closed in early February, resulting in a reduction in our cash balance of $591 million, net of cash acquired.

  • Announced an up to $250 million share repurchase authorization, intended to partially offset dilution associated with stock-based compensation and shares issued as part of the Mentee Robotics acquisition in the first quarter.

JERUSALEM–(BUSINESS WIRE)–
Mobileye Global Inc. (Nasdaq: MBLY) (“Mobileye”) today released its financial results for the three months ended March 28, 2026.

“First quarter results reflected a stronger than expected start to 2026, and continued favorable demand trends enable us to modestly increase our 2026 outlook. We also secured an important design win with Mahindra which adds a third Surround ADAS customer and a second customer for our next-generation SuperVision product,” said Mobileye President and CEO Professor Amnon Shashua. “In parallel, we achieved significant milestones related to our robotaxi technology stack and our EyeQ6H-based Supervision L2++ and Chauffer L3 programs with VW group. Continued execution across these programs is key both to converting our advanced product pipeline into future revenue growth and to winning additional customers.”

First Quarter 2026 Business Highlights

  • The Mobileye Drive / MOIA / VW ID.Buzz robotaxi ecosystem progressed significantly during the first quarter. VW and MOIA announced the kick off of pre-series production at VW’s Hanover plant in March. MOIA announced Orlando as its initial driverless launch location (in collaboration with Beep) and began on-road validation testing with Uber in Los Angeles. There are now more than 100 ID.Buzz AVs powered by Drive testing on public roads in six cities (LA, Austin, Orlando, Munich, Berlin, and Hamburg), with Oslo coming soon. We believe Mobileye Drive technology has meaningful scaling advantages over the competition and look forward to continued strong execution over the course of 2026.

  • For the first time, EyeQ6 High-based SuperVision is operating in the US inside pre-production vehicles. An extended 2,000+ kilometer drive, on an unplanned route, achieved targeted mean-time-between-failure goals in urban, suburban, and highway road types, as well as severe weather, and outperformed other systems used as benchmarks.

  • We announced SuperVision and Surround ADAS design wins with Mahindra. We continue to see significant potential for growth in the India market for both ADAS and AV, and are encouraged that Mahindra believes that advanced mobility products based on Mobileye solutions can serve as competitive differentiators in the mid-trim and premium vehicle segments.

First Quarter 2026 Financial Summary and Key Highlights (Unaudited)

GAAP

U.S. dollars in millions

 

 

Q1 2026

 

 

Q1 2025

 

% Y/Y

Revenue

 

$

558

 

 

$

438

 

 

27

%

Gross Profit

 

$

275

 

 

$

207

 

 

33

%

Gross Margin

 

 

49

%

 

 

47

%

 

+202bps

Operating Income (Loss)

 

$

(3,896

)

 

$

(117

)

 

*NM

Operating Margin

 

 

(698

)%

 

 

(27

)%

 

*NM

Net Income (Loss)

 

$

(3,818

)

 

$

(102

)

 

*NM

EPS – Basic

 

$

(4.68

)

 

$

(0.13

)

 

*NM

EPS – Diluted

 

$

(4.68

)

 

$

(0.13

)

 

*NM

 

 

 

 

 

 

 

*Not Meaningful

Non-GAAP

U.S. dollars in millions

 

 

Q1 2026

 

 

Q1 2025

 

% Y/Y

Revenue

 

$

558

 

 

$

438

 

 

27

%

Adjusted Gross Profit

 

$

370

 

 

$

301

 

 

23

%

Adjusted Gross Margin

 

 

66

%

 

 

69

%

 

(241)bps

Adjusted Operating Income (Loss)

 

$

95

 

 

$

59

 

 

61

%

Adjusted Operating Margin

 

 

17

%

 

 

13

%

 

+360bps

Adjusted Net Income (Loss)

 

$

96

 

 

$

63

 

 

52

%

Adjusted EPS – Basic

 

$

0.12

 

 

$

0.08

 

 

51

%

Adjusted EPS – Diluted

 

$

0.12

 

 

$

0.08

 

 

51

%

  • Revenue increased 27% compared to the first quarter of 2025, primarily due to a 28% ramp up in EyeQ SoC volumes attributable to higher EyeQ demand. A portion of this growth was related to the normalization of safety stock levels at customers, after some draw down that took place in the fourth quarter of 2025.

  • Gross Margin increased by nearly 2 percentage points in the first quarter of 2026 as compared to the prior year period. The increase was primarily due to similar levels of amortization of intangible assets on a significantly higher revenue base, partially offset by a higher EyeQ-related cost per unit given the different mix of EyeQ products sold.

  • Adjusted Gross Margin decreased by nearly 2 percentage points in the first quarter of 2026 as compared to the prior year period. This was mainly due to a higher EyeQ-related cost per unit given the different mix of EyeQ products sold.

  • An additional item that is part of this quarter’s reconciliation of GAAP to Non-GAAP earnings is a non-cash impairment loss related to the Goodwill asset on our balance sheet. This asset originally resulted from the Intel acquisition of Mobileye in 2017 and was pushed down to our balance sheet in connection with the IPO in 2022 and separation from Intel. During the quarter, due to a decline in our market capitalization since the most recent assessment date, as well as increased uncertainty in the macroeconomic and geopolitical environment, an interim impairment test was triggered. The resulting analysis led to an approximately $3,788 million write-down of goodwill. For more information, see our Quarterly Report on Form 10-Q for the period ended March 28, 2026.

  • Operating Margin decreased meaningfully in the first quarter of 2026 as compared to the prior year period. This was primarily due to goodwill impairment loss of $3,788 million recognized in the first quarter of 2026.

  • Adjusted Operating Margin increased to 17% in the first quarter of 2026 as compared to 13% in the prior year period. This is related to significantly higher year-over-year revenue which resulted in lower operating expenses as a percentage of revenue.

  • Operating cash flow for the three months ended March 28, 2026 was $75 million, including transaction costs and cash paid for accelerated options as part of the Mentee Robotics acquisition. Cash used in purchases of property and equipment was $30 million for that same period.

Financial Guidance for the 2026 Fiscal Year

The following information reflects Mobileye’s expectations for Revenue, Operating Loss and Adjusted Operating Income results for the full year 2026. Our updated guidance reflects a 2% increase in expected revenue, at the midpoint, due to higher-than-expected EyeQ unit shipments in the first quarter. Our outlook for Adjusted Operating Income is increased by 8% at the midpoint, reflecting operating leverage on the higher revenue outlook. We are providing a 2026 outlook for Operating Loss now that the Mentee Robotics acquisition has closed. At the time of our Q4 2025 earnings release, prior to closing of the Mentee Robotics acquisition, our outlook for stock-based compensation and amortization of intangible assets was not able to be estimated with precision.

We believe Adjusted Operating Income (a non-GAAP metric) is an appropriate metric as it excludes significant non-cash expenses including: 1) Amortization charges related to intangible assets consisting of developed technology, customer relationships and brands, and developed IP as a result of Intel’s acquisition of Mobileye in 2017 and the acquisition of Mentee Robotics in 2026; 2) Share-based compensation expense; 3) Goodwill impairment; and 4) acquisition-related expenses. These statements represent forward-looking information and may not represent a financial outlook, and actual results may vary. Please see the risks and assumptions referred to in the Forward-Looking Statements section of this release.

 

 

Full Year 2026

U.S. dollars in millions

 

Low

 

High

Revenue

 

$

1,935

 

 

$

2,015

 

Operating Loss

 

$

(4,331

)

 

$

(4,281

)

Amortization of acquired intangible assets

 

$

346

 

 

$

346

 

Share-based compensation expense

 

$

376

 

 

$

376

 

Goodwill impairment

 

$

3,788

 

 

$

3,788

 

Acquisition related expenses

 

$

6

 

 

$

6

 

Adjusted Operating Income

 

$

185

 

 

$

235

 

Earnings Conference Call Webcast Information

Mobileye will host a conference call today, April 23, 2026, at 8:00 am ET (3:00pm IT) to review its results and provide a general business update. The conference call will be accessible live via a webcast on Mobileye’s investor relations site, which can be found at ir.mobileye.com, and a replay of the webcast will be made available shortly after the event’s conclusion.

Non-GAAP Financial Measures

This press release contains Adjusted Gross Profit and Margin, Adjusted Operating Income and Margin, Adjusted Net Income and Adjusted EPS, which are financial measures not presented in accordance with GAAP. We define Adjusted Gross Profit as gross profit presented in accordance with GAAP, excluding amortization of acquisition related intangibles and share-based compensation expense. Adjusted Gross Margin is calculated as Adjusted Gross Profit divided by total revenue. We define Adjusted Operating Income (Loss) as operating loss presented in accordance with GAAP, adjusted to exclude amortization of acquisition related intangibles, share-based compensation expenses, impairment of goodwill and acquisition-related expenses. Operating margin is calculated as Operating Income (Loss) divided by total revenue, and Adjusted Operating Margin is calculated as Adjusted Operating Income divided by total revenue. We define Adjusted Net Income as net loss presented in accordance with GAAP, adjusted to exclude amortization of acquisition related intangibles, share-based compensation expense, impairment of goodwill, acquisition-related expenses and the related income tax effects. Income tax effects have been calculated using the applicable statutory tax rate for each adjustment taking into consideration the associated valuation allowance impacts. The adjustment for income tax effects consists primarily of the deferred tax impact of the amortization of acquired intangible assets. Adjusted Basic EPS is calculated by dividing Adjusted Net Income for the period by the weighted-average number of common shares outstanding during the period. Adjusted Diluted EPS is calculated by dividing Adjusted Net Income (Loss) by the weighted-average number of common shares outstanding during the period, while giving effect to all potentially dilutive common shares to the extent they are dilutive.

We use such non-GAAP financial measures to make strategic decisions, establish business plans and forecasts, identify trends affecting our business, and evaluate performance. For example, we use these non-GAAP financial measures to assess our pricing and sourcing strategy, in the preparation of our annual operating budget, and as a measure of our operating performance. We believe that these non-GAAP financial measures, when taken collectively, may be helpful to investors because they allow for greater transparency into what measures our management uses in operating our business and measuring our performance, and enable comparison of financial trends and results between periods where items may vary independent of business performance. The non-GAAP financial measures are presented for supplemental informational purposes only, should not be considered a substitute for financial information presented in accordance with GAAP, and may be different from similarly titled non-GAAP measures used by other companies. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure presented in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures.

About Mobileye Global Inc.

Mobileye (Nasdaq: MBLY) leads the mobility revolution with our autonomous driving and driver-assistance technologies, harnessing world-renowned expertise in artificial intelligence, computer vision and integrated software and hardware. Since our founding in 1999, Mobileye has enabled the global adoption of advanced driver-assistance systems that save countless lives and reduce crashes, while pioneering groundbreaking technologies such as REM™ crowdsourced road intelligence, Imaging Radar and Compound AI. These technologies drive the ADAS and AV fields towards the future of mobility – enabling self-driving vehicles and mobility solutions at scale, and powering industry-leading ADAS products. Through 2025, more than 230 million vehicles worldwide have been built with Mobileye’s EyeQ technology inside. In 2026, Mobileye acquired Mentee Robotics to pursue the future of physical AI and humanoid robots. Since 2022, Mobileye has been listed independently from Intel (Nasdaq: INTC), which retains majority ownership. For more information, visit https://www.mobileye.com.

“Mobileye,” the Mobileye logo and Mobileye product names are registered trademarks of Mobileye Global. All other marks are the property of their respective owners.

Forward-Looking Statements

Mobileye’s business outlook, guidance and other statements in this release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including Mobileye’s 2026 full-year guidance, projected future revenue and descriptions of our business plan and strategies. These statements often include words such as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast,” or the negative of these terms, and other similar expressions, although not all forward-looking statements contain these words. We base these forward-looking statements or projections, including Mobileye’s full-year guidance, on our current expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances and at such time. You should understand that these statements are not guarantees of performance or results. The forward-looking statements and projections are subject to and involve risks, uncertainties and assumptions and you should not place undue reliance on these forward-looking statements or projections. Although we believe that these forward-looking statements and projections are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results or results of operations and could cause actual results to differ materially from those expressed in the forward-looking statements and projections.

Important factors that may materially affect such forward-looking statements and projections include the following: further deterioration of macroeconomic conditions due to ongoing global economic and political uncertainty; future business, strategic and financial performance, goals and measures; our anticipated growth prospects and trends in markets and industries relevant to our business; business and investment plans; expectations about our ability to maintain or enhance our leadership position in the markets in which we participate; future consumer demand and behavior, including expectations about excess inventory utilization by customers; our ability to effectively compete in the markets in which we operate; increased competition from emerging chip manufacturers and OEMs; future products and technology, and the expected availability and benefits of such products and technology; the humanoid robotics industry and its accompanying technology may not develop as expected; development of regulatory frameworks for current and future technology; changes in regulation and trade policy, including increased tariffs, in regions in which we operate, including the U.S., Europe and China; projected cost and pricing trends; future production capacity and product supply; potential future benefits and competitive advantages associated with our technologies and architecture and the data we have accumulated; the future purchase, use and availability of products, components and services supplied by third parties, including third-party IP and manufacturing services; uncertain events or assumptions, including statements relating to our estimated vehicle production and market opportunity, potential production volumes associated with design wins and other characterizations of future events or circumstances; adverse conditions in Israel, including as a result of war and geopolitical conflict, which may affect our operations and may limit our ability to produce and sell our solutions; any disruption in our operations by the obligations of our personnel to perform military service as a result of current or future military actions involving Israel; availability, uses, sufficiency and cost of capital and capital resources, including expected returns to stockholders such as dividends, and the expected timing of future dividends; tax- and accounting-related expectations; sustained low levels of our share price and market capitalization as well as other factors may require further testing of our Mobileye reporting unit, which may result in an impairment of goodwill; the ability to meet our social and environmental goals and projections.

The estimates included herein are based on projections of future production volumes that were provided by our current and prospective OEMs at the time of sourcing the design wins for the models related to those design wins. For the purpose of these estimates, we estimated sales prices based on our management’s estimates for the applicable product bundles and periods. Achieving design wins is not a guarantee of revenue, and our sales may not correlate with the achievement of additional design wins. Moreover, our pricing estimates are made at the time of a request for quotation by an OEM (in the case of estimates related to contracted customers), so that worsening market or other conditions between the time of a request for quotation and an order for our solutions may require us to sell our solutions for a lower price than we initial expected. These estimates may deviate from actual production volumes and sale prices (which may be higher or lower than the estimates) and the amounts included for prospective but uncontracted production volumes may never be achieved. Accordingly, these estimations are subject to and involve risks, uncertainties and assumptions and you should not place undue reliance on these forward-looking statements or projections.

Detailed information regarding these and other factors that could affect Mobileye’s business and results is included in Mobileye’s SEC filings, including the company’s Annual Report on Form 10-K for the year ended December 27, 2025, particularly in the section entitled “Item 1A. Risk Factors”. Copies of these filings may be obtained by visiting our Investor Relations website at ir.mobileye.com or the SEC’s website at www.sec.gov.

First Quarter 2026 Financial Results

Mobileye Global Inc.

Condensed Consolidated Statements of Operations (unaudited)

 

 

Three Months Ended

U.S. dollars in millions, except share and per share amounts

 

March 28, 2026

 

March 29, 2025

Revenue

 

$

558

 

 

$

438

 

Cost of revenue

 

 

283

 

 

 

231

 

Gross profit

 

 

275

 

 

 

207

 

Research and development, net

 

 

323

 

 

 

275

 

Sales and marketing

 

 

29

 

 

 

31

 

General and administrative

 

 

31

 

 

 

18

 

Goodwill impairment

 

 

3,788

 

 

 

 

Total operating expenses

 

 

4,171

 

 

 

324

 

Operating income (loss)

 

 

(3,896

)

 

 

(117

)

Financial income (expense), net

 

 

14

 

 

 

18

 

Income (loss) before income taxes

 

 

(3,882

)

 

 

(99

)

Benefit (provision) for income taxes

 

 

64

 

 

 

(3

)

Net income (loss)

 

$

(3,818

)

 

$

(102

)

 

 

 

 

 

Earnings (loss) per share attributed to Class A and Class B stockholders:

 

 

 

 

Basic and diluted

 

$

(4.68

)

 

$

(0.13

)

Weighted-average number of shares used in computation of earnings (loss) per share attributed to Class A and Class B stockholders (in millions):

 

 

 

 

Basic and diluted

 

 

817

 

 

 

812

 

Mobileye Global Inc.

Condensed Consolidated Balance sheets (unaudited)

U.S. dollars in millions

 

March 28, 2026

 

December 27, 2025

Assets

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

 

$

1,211

 

$

1,836

Marketable securities and deposits

 

 

133

 

 

55

Trade accounts receivable, net

 

 

226

 

 

131

Inventories

 

 

303

 

 

327

Other current assets

 

 

120

 

 

129

Total current assets

 

 

1,993

 

 

2,478

Non-current assets:

 

 

 

 

Property and equipment, net

 

 

468

 

 

473

Intangible assets, net

 

 

1,181

 

 

1,166

Goodwill

 

 

4,911

 

 

8,200

Other long-term assets

 

 

182

 

 

175

Total non-current assets

 

 

6,742

 

 

10,014

TOTAL ASSETS

 

$

8,735

 

$

12,492

Liabilities and Equity

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable and accrued expenses

 

$

228

 

$

228

Employee related accrued expenses

 

 

137

 

 

141

Related party payable

 

 

3

 

 

4

Other current liabilities

 

 

51

 

 

33

Total current liabilities

 

 

419

 

 

406

Non-current liabilities:

 

 

 

 

Long-term employee benefits

 

 

78

 

 

78

Deferred tax liabilities

 

 

5

 

 

60

Other long-term liabilities

 

 

69

 

 

67

Total non-current liabilities

 

 

152

 

 

205

TOTAL LIABILITIES

 

$

571

 

$

611

TOTAL EQUITY

 

 

8,164

 

 

11,881

TOTAL LIABILITIES AND EQUITY

 

$

8,735

 

$

12,492

Mobileye Global Inc.

Condensed Consolidated Cash Flows (unaudited)

 

 

Three Months Ended

U.S. dollars in millions

 

March 28, 2026

 

March 29, 2025

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

Net income (loss)

 

$

(3,818

)

 

$

(102

)

 

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

 

 

 

 

 

Depreciation of property and equipment

 

 

20

 

 

 

18

 

 

Share-based compensation

 

 

80

 

 

 

65

 

 

Amortization of intangible assets

 

 

113

 

 

 

111

 

 

Goodwill impairment

 

 

3,788

 

 

 

 

 

Exchange rate differences on cash and cash equivalents

 

 

(2

)

 

 

(2

)

 

Deferred income taxes

 

 

(72

)

 

 

(6

)

 

Changes in operating assets and liabilities:

 

 

 

 

 

Decrease (increase) in trade accounts receivable

 

 

(95

)

 

 

(5

)

 

Decrease (increase) in other current assets

 

 

8

 

 

 

15

 

 

Decrease (increase) in inventories

 

 

24

 

 

 

51

 

 

Decrease (increase) in other long-term assets

 

 

 

 

 

3

 

 

Increase (decrease) in accounts payable, accrued expenses and related party payable

 

 

14

 

 

 

(36

)

 

Increase (decrease) in employee-related accrued expenses and long-term benefits

 

 

(5

)

 

 

 

 

Increase (decrease) in other current liabilities

 

 

18

 

 

 

(5

)

 

Increase (decrease) in other long-term liabilities

 

 

2

 

 

 

2

 

 

Net cash provided by operating activities

 

 

75

 

 

 

109

 

 

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

 

 

Purchase of property and equipment

 

 

(30

)

 

 

(14

)

 

Purchases of debt and equity investments

 

 

(125

)

 

 

(25

)

 

Maturities and sales of debt and equity investments

 

 

47

 

 

 

14

 

 

Cash paid for acquisition of Mentee Robotics, net of cash acquired

 

 

(591

)

 

 

 

 

Net cash used in investing activities

 

 

(699

)

 

 

(25

)

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

Share-based compensation recharge

 

*

 

 

3

 

 

Net cash provided by financing activities

 

 

 

 

 

3

 

 

Effect of foreign exchange rate changes on cash and cash equivalents

 

 

2

 

 

 

2

 

 

Increase (decrease) in cash, cash equivalents and restricted cash

 

 

(622

)

 

 

89

 

 

Balance of cash, cash equivalents and restricted cash, at beginning of year

 

 

1,860

 

 

 

1,438

 

 

Balance of cash, cash equivalents and restricted cash, at end of period

 

$

1,238

 

 

$

1,527

 

 

 

* Less than $1 million.

Mobileye Global Inc.

Reconciliation of GAAP Gross Profit and Margin to Non-GAAP Adjusted Gross Profit and Margin1 (unaudited)

 

Three Months Ended

U.S. dollars in millions

March 28, 2026

 

March 29, 2025

 

Amount

 

% of Revenue

 

Amount

 

% of Revenue

Gross Profit and Margin

$

275

 

49

%

 

$

207

 

47

%

Add: Amortization of acquired intangible assets

 

95

 

17

%

 

 

94

 

21

%

Add: Share-based compensation expense

 

 

%

 

 

 

%

Adjusted Gross Profit and Margin

$

370

 

66

%

 

$

301

 

69

%

 

1Adjusted gross margin is calculated as adjusted gross profit as a percentage of revenue

Mobileye Global Inc.

Reconciliation of GAAP Operating Income and Margin to Non-GAAP Adjusted Operating Income and Margin2 (unaudited)

 

Three Months Ended

U.S. dollars in millions

March 28, 2026

 

March 29, 2025

 

Amount

 

% of Revenue

 

Amount

 

% of Revenue

Operating Income (Loss) and Margin

$

(3,896

)

 

(698

)%

 

$

(117

)

 

(27

)%

Add: Amortization of acquired intangible assets

 

113

 

 

20

%

 

 

111

 

 

25

%

Add: Share-based compensation expense

 

84

 

 

15

%

 

 

65

 

 

15

%

Add: Acquisition related expenses

 

6

 

 

1

%

 

 

 

 

%

Add: Goodwill impairment

 

3,788

 

 

679

%

 

 

 

 

%

Adjusted Operating Income (Loss) and Margin

$

95

 

 

17

%

 

$

59

 

 

13

%

 

2Adjusted operating margin is calculated as adjusted operating income (loss) as a percentage of revenue

Mobileye Global Inc.

Reconciliation of GAAP Net Income to Non-GAAP Adjusted Net Income (unaudited)

 

Three Months Ended

U.S. dollars in millions

March 28, 2026

 

March 29, 2025

 

Amount

 

% of Revenue

 

Amount

 

% of Revenue

Net Income (Loss)

$

(3,818

)

 

(684

)%

 

$

(102

)

 

(23

)%

Add: Amortization of acquired intangible assets

 

113

 

 

20

%

 

 

111

 

 

25

%

Add: Share-based compensation expense

 

84

 

 

15

%

 

 

65

 

 

15

%

Add: Acquisition related expenses

 

6

 

 

1

%

 

 

 

 

%

Add: Goodwill impairment

 

3,788

 

 

679

%

 

 

 

 

%

Less: Income tax effects

 

(77

)

 

(14

)%

 

 

(11

)

 

(3

)%

Adjusted Net Income (Loss)

$

96

 

 

17

%

 

$

63

 

 

14

%

Supplemental Information – Average System Price (unaudited)3

 

Q1 2025

 

Q2 2025

 

Q3 2025

 

Q4 2025

 

Q1 2026

EyeQ and SuperVision revenue (U.S. dollars in millions)

$

415

 

$

481

 

$

478

 

$

420

 

$

535

Number of systems shipped (in millions)

 

8.5

 

 

9.7

 

 

9.2

 

 

8.3

 

 

10.8

Average system price (U.S. dollars)

$

49.0

 

$

49.7

 

$

51.7

 

$

50.8

 

$

49.3

 

3 Average System Price is calculated as the sum of revenue related to EyeQ™ and SuperVision systems, divided by the number of systems shipped.

 

Dan Galves

Investor Relations

[email protected]

Justin Hyde

Media Relations

[email protected]

KEYWORDS: United States North America Israel Middle East

INDUSTRY KEYWORDS: Other Energy Automotive Manufacturing Technology Manufacturing Other Technology Alternative Energy Energy

MEDIA:

Logo
Logo

Primech Holdings Accelerates U.S. Expansion for Primech AI’s Hytron, Selected for SelectUSA Tech Amid Growing Institutional Deployment Pipeline

Company Advances Nationwide Commercial Rollout as Demand for Automation Surges Across U.S. Facilities Sector

SINGAPORE, April 23, 2026 (GLOBE NEWSWIRE) — Primech Holdings Limited (Nasdaq: PMEC) (“Primech” or the “Company”), through its autonomous robotics subsidiary Primech AI Pte. Ltd., today announced the acceleration of its U.S. expansion strategy, supported by its selection for the SelectUSA Tech program and participation in the 2026 SelectUSA Investment Summit (May 3–6, 2026, National Harbor, Maryland) following an invitation from the U.S. Embassy in Singapore. This acceleration positions Primech to capitalize on intensifying enterprise demand for AI-powered facility automation and supports the Company’s long-term growth strategy through institutional-scale commercial deployment in the world’s largest facilities services market.

The Company is actively advancing a growing pipeline of commercial deployment opportunities across the United States for Hytron, its flagship fully autonomous AI-powered restroom cleaning system, as enterprise demand intensifies for scalable automation solutions addressing persistent labor shortages and rising operating costs.

Primech’s participation comes at a landmark bilateral moment as Singapore and the United States mark 60 years of diplomatic relations and the United States celebrates the 250th anniversary of its independence. According to the U.S. Department of Commerce, SelectUSA facilitated approximately US$139 billion in foreign direct investment deals over the past year, supporting more than 32,000 American jobs across 175 transactions, with the 2025 Summit drawing more than 5,500 participants and over 2,700 business investors from more than 100 countries.

Following successful showcases at CMS Berlin and the Tokyo Building & Maintenance Show, and its North American debut at CES 2026, Primech is now executing the next phase of its global strategy: large-scale commercial deployment in the United States.

Hytron generated more than 350 qualified enterprise leads from 23 countries at CES 2026, including significant engagement from U.S.-based operators across healthcare, hospitality, transportation, higher education, and commercial real estate. The Company is currently progressing discussions with multiple large-scale U.S. facility operators, including leading hospitality and institutional services providers. Mass production of Hytron commenced in the second quarter of 2026, and Primech has executed distribution agreements across multiple international markets to support scaled commercial rollout.

Primech has already established a foundational U.S. operating platform to support commercialization and scale, including its Delaware incorporation, Edwardsville, Illinois office, and operational collaborations with robotic service and distribution partners. The Company is evaluating opportunities to expand its U.S. footprint further, including deployment infrastructure, servicing capabilities, and potential localized operations to support nationwide scale.

Primech’s selection for SelectUSA Tech highlights its alignment with key U.S. priorities including workforce resilience, supply chain diversification, and the integration of advanced automation into institutional operations. Hytron has demonstrated greater than 99% bacterial reduction in independent testing and received a TechRadar Pro Picks Award at CES 2026.

“The United States represents the most significant near-term growth opportunity for Primech AI,” said Ken Ho, Chairman and Chief Executive Officer of Primech Holdings Limited. “Our selection for SelectUSA Tech and the invitation from the U.S. Embassy in Singapore reflect the tangible operational investments we have made to prepare for scaled U.S. commercialization, from our Delaware subsidiary and Edwardsville office to active engagement with leading American institutional operators. With Hytron mass production having commenced in the second quarter of 2026, distribution agreements in place across multiple international markets, and a clear pipeline of U.S. enterprise deployment opportunities, we are positioned to convert this momentum into meaningful commercial traction, expanded U.S. operational capabilities, and long-term value creation for Primech shareholders.”

During the Summit, Primech will engage with U.S. state and local economic development organizations, federal agency representatives, and prospective commercial and channel partners to advance Hytron deployment, expand strategic partnerships, and accelerate U.S. market entry. The Company will provide updates on the outcomes of these engagements through subsequent investor communications.

About Primech Holdings Limited

Headquartered in Singapore, Primech Holdings Limited (Nasdaq: PMEC) is a leading provider of comprehensive technology-driven facilities services, predominantly serving both public and private sectors throughout Singapore. Primech Holdings offers an extensive range of services tailored to meet the complex demands of its diverse clientele. Services include advanced general facility maintenance services, specialized cleaning solutions such as marble polishing and facade cleaning, meticulous stewarding services, and targeted cleaning services for offices and homes. Known for its commitment to sustainability and cutting-edge technology, Primech Holdings integrates eco-friendly practices and smart technology solutions to enhance operational efficiency and client satisfaction. For more information, visit www.primechholdings.com.

About Primech AI

Primech AI Pte. Ltd., a subsidiary of Primech Holdings Limited, is a robotics company dedicated to developing autonomous, AI-powered solutions for commercial facility operations. Its flagship product, HYTRON, is a fully autonomous AI-powered restroom cleaning robot engineered to enhance hygiene standards, reduce labor dependency, and support sustainability initiatives across high-traffic environments including airports, healthcare facilities, hotels, transportation hubs, educational institutions, and commercial real estate. For more information, visit www.primech.ai.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, including, for example, statements about anticipated U.S. market expansion, commercial deployments, partnership development, manufacturing initiatives, and long-term shareholder value creation. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. These forward-looking statements are also based on assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “likely to,” or other similar expressions. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, some of which are beyond the Company’s control. Actual results may differ materially from those projected. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. For a discussion of risk factors, please refer to the Company’s filings with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov.

Contact

Primech Holdings Limited

Investor Relations

[email protected]

www.primechholdings.com



urban-gro, Inc. (Nasdaq: UGRO) — Sri Lanka Cricket Confirms July 10 – August 5, 2026 and Four Venues for Lanka Premier League Season 6; Tournament Conducted in Partnership with UGRO Subsidiary IPG Group

Foreign player registration portal opens May 4, 2026; matches to be played across SSC (Colombo), R. Premadasa (Colombo), Pallekele (Kandy), and Rangiri Dambulla

LAFAYETTE, Colo., April 23, 2026 (GLOBE NEWSWIRE) — urban-gro, Inc. (Nasdaq: UGRO) (“urban-gro” or the “Company”), operating through Flash Sports & Media, Inc., today noted the official announcement by Sri Lanka Cricket (“SLC”) confirming the dates, venues, and player-registration timeline for Lanka Premier League (“LPL”) Season 6. The tournament will run from July 10 to August 5, 2026, and is owned by SLC and conducted in partnership with Innovative Production Group FZ, LLC (“IPG”), the event rights holder. The Company participates in the tournament through its subsidiary, IPG under existing commercial arrangements.

Season 6 — By the Numbers

Tournament window July 10 – August 5, 2026 (confirmed by Sri Lanka Cricket)
Venues SSC (Colombo), R. Premadasa (Colombo), Pallekele (Kandy), Rangiri Dambulla
Foreign player registration Portal opens May 4, 2026
League ownership Owned by Sri Lanka Cricket; conducted in partnership with The IPG Group (event rights holder)
UGRO involvement Through subsidiary Innovative Production Group FZ, LLC (IPG) under existing commercial arrangements
Tournament Director Samantha Dodanwela, SLC Executive Committee Member



Confirmed Venues

Season 6 matches will be played across four Sri Lankan international cricket venues:

  • Singhalese Sports Club (SSC) Grounds, Colombo
  • R. Premadasa International Cricket Stadium (RPICS), Colombo
  • Pallekele International Cricket Stadium (PICS), Kandy
  • Rangiri Dambulla International Cricket Stadium (RDICS), Dambulla

Samantha Dodanwela, an Executive Committee Member of SLC, will continue to serve as Tournament Director. The online portal for foreign player registration is scheduled to open on May 4, 2026.

Strategic Context for UGRO

Following its combination with Flash Sports & Media, Inc. and the integration of IPG, the Company participates in the LPL as a sports, media, and experiential platform, with commercial exposure to the tournament’s media, sponsorship, and on-ground activations through its contractual arrangements with the league. LPL Season 6 represents the first full season in the Company’s current operating structure following the IPG integration. Actual revenues from the Company’s participation will depend on the specific terms of its contractual arrangements and on overall tournament outcomes, and may differ materially from any industry-level references included in this release.

Industry Context (Third-Party Data)

For general reference only, publicly available third-party reports describe T20 cricket as a high-engagement global format with an estimated fan base of approximately 2.5 billion across South Asia, Southeast Asia, the Caribbean, the United Kingdom, and other markets. IPL media rights, for a mature comparable league, have been publicly reported at over USD 6 billion for a five-year cycle. Third-party industry estimates have referenced local economic impact for prior LPL seasons in the USD 25–30 million range. These figures relate to the broader industry or to other leagues and are not a projection of the Company’s financial results, revenues, or economic impact from LPL Season 6, and should not be relied on as such.

Additional Season 6 Developments (Subject to Confirmation)

Separate from the SLC-confirmed schedule above, the league has discussed the following Season 6 elements, each of which remains subject to final registration, contractual arrangements, governing-body and board approvals, and NOCs, and none of which is guaranteed to occur:

  • An expected player registration pool in the range of 500 to 600 athletes for the season
  • Expected appointment of Chris Gayle as official Brand Ambassador for Season 6
  • Participation interest from marquee international players who have historically played in global T20 competitions, including players from Australia, England, South Africa, New Zealand, the West Indies, Pakistan, Afghanistan, Bangladesh, and India

Individual player participation is not confirmed and is subject to final registration, availability, and applicable approvals. References to individual players should not be read as current commitments.

“With the tournament dates and venues now confirmed, the focus turns to player registration opening in May and building out the commercial, broadcast, and on-ground plan for Season 6.”

— Anil Mohan, CEO, The IPG Group

Disclaimer

The Company does not own, operate, or control the Lanka Premier League, its franchises, or any governing body. The Company’s involvement is limited to its contractual rights and services through Innovative Production Group FZ, LLC and related commercial arrangements. References to league operations, player participation, market size, or economic impact are based on third-party information or industry estimates and are provided solely for general context. The Company’s actual revenues, if any, will depend on its specific contractual arrangements and may differ materially from broader industry metrics referenced herein.

About urban-gro, Inc.

Following its recent combination with Flash Sports & Media, Inc. (“Flash”) and the integration of Innovative Production Group FZ, LLC, urban-gro, Inc. is a diversified sports, media, and experiential marketing platform focused on the creation, production, and monetization of live events, original content, and branded fan experiences. The Company operates across multiple sports and entertainment verticals, leveraging proprietary intellectual property, strategic partnerships, and experiential activations to engage audiences and deliver value for brands, sponsors, and media partners.

About Lanka Premier League

The Lanka Premier League is a professional T20 cricket tournament bringing together Sri Lankan and international players. The league is owned by Sri Lanka Cricket and operated in partnership with The IPG Group, its official event rights holder. Season 6 will be played from July 10 through August 5, 2026. For additional information, visit: https://srilankacricket.lk

About Twenty20 Cricket

Twenty20 (T20) is a format of cricket in which each team plays a maximum of 20 overs. Introduced by the England and Wales Cricket Board in 2003, T20 matches are typically completed in approximately three and a half hours. For more information, visit: http://www.t20worldcup.com

Investor Relations Contact

[email protected]

Company Websites

https://flashsportsandmedia.com
https://www.theipggroup.com

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the Company’s expectations, beliefs, or intentions relating to its participation in connection with the Lanka Premier League, the anticipated benefits of its business combination with Flash Sports & Media, Inc., the development and commercialization of sports and media platforms, potential sponsorship, media rights and commercial opportunities, anticipated market size and growth, projected economic impact of the Lanka Premier League, and the Company’s ability to generate revenues from its activities. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “plan,” “may,” “will,” “could,” “seek,” “estimate,” “potential,” or similar expressions.

These forward-looking statements are based on current expectations, estimates, and assumptions and involve known and unknown risks and uncertainties that could cause actual results and outcomes to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, without limitation: the Company’s limited role and lack of control over the operations, scheduling, governance, and commercial activities of the Lanka Premier League and its franchises; the Company’s reliance on third-party partners, including Innovative Production Group FZ LLC and other counterparties, to perform under contractual arrangements; uncertainties regarding the participation, availability, or continued involvement of players, ambassadors, or other talent referenced in this press release; the possibility that anticipated sponsorships, media rights arrangements, or other commercial opportunities may not materialize or may be delayed; the extent to which the Company is able to generate revenues, if any, from its involvement in the Lanka Premier League; risks relating to the integration of Flash Sports & Media, Inc. and the Company’s ability to realize anticipated synergies; the Company’s ability to develop, monetize, and scale its sports, media, and experiential business lines; the timing and success of expansion into new markets; the Company’s ability to establish or maintain strategic relationships and commercial arrangements; the extent to which industry developments referenced in this press release translate into opportunities for the Company; general economic, market, and industry conditions; competitive dynamics within the sports and media sectors; international, geopolitical, and regulatory risks associated with global sporting events; and the Company’s ability to maintain compliance with applicable listing standards of The Nasdaq Stock Market LLC.

In addition, certain market, industry, and economic data referenced in this press release are based on third-party sources and estimates that the Company believes to be reliable, but the Company has not independently verified such information and makes no representation as to its accuracy or completeness.

Additional factors that could cause actual results to differ materially from those described in forward-looking statements can be found in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, as well as other filings made with the Securities and Exchange Commission, which are available at www.sec.gov.

Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Source: urban-gro, Inc. (Nasdaq: UGRO)



The Joint Corp. to Report 2026 First Quarter Results on Thursday, May 7 and Host Conference Call and Webcast

SCOTTSDALE, Ariz., April 23, 2026 (GLOBE NEWSWIRE) — The Joint Corp. (NASDAQ: JYNT), the nation’s largest franchisor of chiropractic care through The Joint Chiropractic® network, announced it will report its 2026 first quarter financial results on Thursday, May 7, 2026, after the market close and host a conference call and simultaneous webcast at 5:00 p.m. ET that day. During the call, The Joint Corp. President and CEO Sanjiv Razdan and CFO Scott Bowman will review the Company’s financial results and provide a business update, followed by a question-and-answer session.

Shareholders and interested participants may listen to a live broadcast of the conference call by dialing (833) 630-0823 or (412) 317-1831 and asking to be joined into the ‘The Joint’ call approximately 15 minutes prior to the start time.

The live webcast of the call with an accompanying slide presentation can be accessed in the IR events section of The Joint’s website at https://ir.thejoint.com/events. A replay of the webcast will be archived on the Company’s investor relations website for approximately one year. An audio replay of the conference call will be available through Thursday, May 14, 2026, and can be accessed by dialing (855) 669-9658 or (412) 317-0088 and entering conference ID 6402682.

About The Joint Corp. (NASDAQ: JYNT)

The Joint Corp. (NASDAQ: JYNT) revolutionized access to chiropractic care when it introduced its retail healthcare business model in 2010. Today, it is the nation’s largest operator, manager and franchisor of chiropractic clinics through The Joint Chiropractic network. The company is making quality care convenient and affordable, while eliminating the need for insurance, for millions of patients seeking pain relief and ongoing wellness. Headquartered in Scottsdale and with over 950 locations nationwide and more than 14 million patient visits annually, The Joint Chiropractic is a key leader in the chiropractic industry. The brand is consistently named to Franchise Times’ annual “Top 400” and “Fast & Serious” list of 40 smartest growing brands. Entrepreneur named The Joint “No. 1 in Chiropractic Services,” and it is regularly ranked on the publication’s “Franchise 500,” the “Fastest-Growing Franchises,” and the “Best of the Best” lists, as well as its “Top Franchise for Veterans” and “Top Brands for Multi-Unit Owners” lists. SUCCESS named the company as one of the “Top 50 Franchises” in 2024. The Joint Chiropractic is an innovative force, where healthcare meets retail. For more information, visit www.thejoint.com. To learn about franchise opportunities, visit www.thejointfranchise.com.

The Joint Business Structure

The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Tennessee, Washington, and West Virginia, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.

Investor Contact:

Richard Land, Alliance Advisors IR, [email protected], 212-838-3777



NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration

NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration

EHR-enabled access has the potential to streamline ordering, accelerate clinical decisions, and drive scalable precision oncology adoption

FORT MYERS, Fla.–(BUSINESS WIRE)–NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that its oncology testing portfolio is now available through Epic Aura, enabling seamless access to oncologists and health systems across the United States through the Epic electronic health record (EHR) workflow.

Through this integration, physicians can order NeoGenomics’ comprehensive suite of tests, spanning solid tumors and hematologic malignancies, and view results in the same system they use to manage patient care. This streamlined approach lowers barriers to entry for hospitals and health systems, enhances the scalability of NeoGenomics’ testing capabilities, and could drive 20-30% increase1 in test adoption per site, supporting faster time to treatment for patients facing a cancer diagnosis.

“Clinicians need timely access to the right diagnostics within the systems they already rely on,” said Tony Zook, Chief Executive Officer of NeoGenomics. “Successfully integrating with Epic enables us to bring our testing capabilities directly into everyday care delivery, with the potential to help patients begin appropriate therapy sooner while allowing health systems to scale precision oncology more efficiently.”

This integration represents a significant step forward in NeoGenomics’ digital health strategy, strengthening connectivity across community oncology practices and large health systems. This scalable, “build once, deploy broadly” infrastructure will support the delivery of next-generation diagnostic capabilities, including liquid biopsy and molecular residual disease (MRD).

About NeoGenomics

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.

Forward Looking Statements

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “can,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,” “intend,” “seek,” “target” and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Epic Aura integration, including the potential to streamline test ordering, accelerate clinical decisions, drive adoption of precision oncology, increase test adoption per site and support faster time to treatment, as well as the Company’s Digital Health strategy and the anticipated delivery of next-generation diagnostic capabilities. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, risks related to the Company’s ability to successfully implement and maintain the Epic Aura integration, the willingness of health systems and physicians to adopt the integrated ordering workflow, the Company’s ability to achieve projected increases in test adoption, the timing and success of the Company’s Digital Health strategy, general market conditions, competitive dynamics and the risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company’s other filings with the Securities and Exchange Commission.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and in the “Investors” section of our website at ir.neogenomics.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements, whether as a result of new information, future events or otherwise, except as required by law. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Reference

1. Huelsman K, Vasiliadis L, Liette A, Wernke K, Parchman A, Maher J, Rice C. Integrating discrete genomic data with an EHR improves patient care, provider satisfaction, and program metrics. Association of Cancer Care Centers. 2024;39(2):12-24. Accessed April 21, 2026. https://cdn.sanity.io/files/0vv8moc6/accc-cancer/b351ee63a2f4679660f6e409dd3564c61d15e212.pdf

Investor Contact

[email protected]

Media Contact

Andrea Sampson

[email protected]

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Hospitals Health Practice Management Health Technology Oncology

MEDIA:

Logo
Logo

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

– Separate poster will feature long-term safety and tolerability data from STARS clinical trial program of apraglutide in adults with SBS who are dependent on parenteral support (PS) –

– Linaclotide data presentations highlight efficacy and safety insights in IBS-C, CIC and pediatric FC –

BOSTON–(BUSINESS WIRE)–Ironwood Pharmaceuticals, Inc.(Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, announced today that the company will present data from its LANDMARK survey during the 2026 Digestive Disease Week® (DDW) meeting being held from May 2-5 in Chicago, IL. The data will spotlight healthcare professional (HCP) insights on the burden of total parenteral nutrition (TPN) for patients with short bowel syndrome (SBS), as well as preferred attributes for potential new therapies that reduce TPN dependence.

SBS is a serious and chronic condition characterized by reduced absorptive capacity for fluids and/or nutrients, often requiring long-term dependence on parenteral support (PS) (IV nutrition and/or IV hydration) to sustain life. Patients with SBS who are chronically dependent on PS, also referred to as SBS with intestinal failure (SBS-IF), frequently experience significant treatment burden, reduced quality of life and increased risk of severe complications such as infection. Despite current management approaches, substantial unmet need remains for therapies that reduce PS dependence and improve outcomes. An estimated 18,000 adult patients suffer from SBS-IF in the U.S., Europe and Japan, and have chronic dependence on PS.

Ironwood is advancing apraglutide, an investigational, next-generation, long-acting synthetic GLP-2 analog, for SBS patients dependent on PS.

“Short bowel syndrome remains a complex and underserved condition where patients and clinicians face significant challenges, particularly for those who rely on parenteral support, which is often life-sustaining but can be associated with substantial treatment burden,” said Michael Shetzline, M.D., Ph.D., chief medical officer, senior vice president and head of research and drug development at Ironwood Pharmaceuticals. “By bringing forward real-world healthcare professional perspectives, we aim to deepen understanding of current management and the factors that shape SBS-IF care in everyday practice and help inform future therapeutic approaches.”

In addition to the LANDMARK survey data, Ironwood will present long-term safety and tolerability data from the STARS clinical trial program of apraglutide in adults with SBS who are dependent on PS. Additional presentations include key findings from the company’s Phase 3 open-label safety extension study oflinaclotide in pediatric patients aged 2–5 years with functional constipation, as well as analyses in adults with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC).

A full list of the poster presentations is below.

Short Bowel Syndrome

  • “Burden of Total Parenteral Nutrition for Patients with Short Bowel Syndrome Dependent on Parenteral Support: Healthcare Professional Perspectives on Risks, Limitations, and Treatment Priorities” (Sunday, May 03, 12:30 pm CT) will be presented by Mena Boules, M.D., Ironwood Pharmaceuticals.

  • “Long-Term Safety and Tolerability of Once-Weekly Apraglutide in Patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF)” (Sunday, May 03, 12:30 pm CT) will be presented by Palle Bekker Jeppesen, M.D., Dr.med/Sci., Ph.D., dls., Rigshospitalet, Copenhagen.

IBS-C, CIC and Functional Constipation

  • “Effect of pH-Modifying Agents on the Efficacy and Safety of Linaclotide in Adults with Chronic Idiopathic Constipation (CIC) or Irritable Bowel Syndrome with Constipation (IBS-C): A Post Hoc Analysis” (Saturday, May 02, 12:30 pm CT) will be presented by Satish SC Rao, M.D., Ph.D., FRCP (LON), FACG, AGAF, Augusta University.

  • “Safety and Efficacy of Linaclotide in Pediatric Patients Aged 2–5 Years with Functional Constipation (FC): Results from an Open-Label Safety Extension of a Phase 3 Study” (Monday, May 04, 12:30 pm CT) will be presented by Carlo Di Lorenzo, M.D., Nationwide Children’s Hospital.

  • “Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome with Constipation (IBS-C): A Phase 3 Post Hoc Analysis by Race, Ethnicity and Age” (Saturday, May 02, 12:30 pm CT) will be presented by Aditya Ashok, M.D., Weill Cornell Medical College.

  • “Linaclotide Efficacy in Adults with Severe Chronic Idiopathic Constipation (CIC): A Post Hoc Pooled Analysis of Phase 3 Studies” (Monday, May 04, 12:30 pm CT) will be presented by Anthony J. Lembo, M.D., Digestive Disease Institute, Cleveland Clinic.

About the LANDMARK Survey

The LANDMARK disease burden survey is a cross-sectional study of HCPs, patients and caregivers assessing the real-world burden of SBS and PS dependence. The HCP survey recruited 336 participants (U.S., n=123; Europe, n=213) with two or more years of experience treating patients with SBS-IF and actively managing one or more patients. Respondents included physicians (42.0%), pharmacists (23.0%) and dietitians (18.0%), practicing primarily in gastroenterology (45.2%), clinical nutrition/nutritional support (23.5%) and internal medicine (17.3%).

About Apraglutide

Apraglutide is an investigational, next-generation, long-acting synthetic GLP-2 analog with the potential to treat a range of rare gastrointestinal diseases where GLP-2 can play a central role in addressing disease pathophysiology. Ironwood is advancing apraglutide for short bowel syndrome (“SBS”) patients dependent on parenteral support (“PS”), a severe chronic malabsorptive condition. As the first and only GLP-2 to achieve a statistically significant reduction in weekly parenteral support volume with once-weekly administration, Ironwood believes apraglutide has the potential to improve the standard of care for adult patients with SBS who are dependent on PS.

About LINZESS (Linaclotide)

LINZESS® is the #1 prescribed brand in the U.S. for the treatment of patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), based on IQVIA data. LINZESS is a once-daily capsule that helps relieve the abdominal pain and constipation, associated with IBS-C in adults and pediatric patients 7 years of age and older. LINZESS has also been shown to relieve constipation, infrequent stools, hard stools, straining and incomplete evacuation associated with CIC in adult patients. LINZESS relieves constipation in children and adolescents aged 6 to 17 years with functional constipation.

LINZESS is not a laxative; it is the first medicine approved by the FDA in a class called GC-C agonists. LINZESS contains a peptide called linaclotide that activates the GC-C receptor in the intestine. Activation of GC-C is thought to result in increased intestinal fluid secretion and accelerated transit and a decrease in the activity of pain-sensing nerves in the intestine. The clinical relevance of the effect on pain fibers, which is based on nonclinical studies, has not been established.

In the United States, Ironwood and AbbVie co-develop and co-commercialize LINZESS for the treatment of adults with IBS-C or CIC. In Europe, AbbVie markets linaclotide under the brand name CONSTELLA® for the treatment of adults with moderate to severe IBS-C. In Japan, Ironwood’s partner, Astellas, markets linaclotide under the brand name LINZESS for the treatment of adults with IBS-C or CIC. Ironwood also has partnered with AstraZeneca for development and commercialization of LINZESS in China, and with AbbVie for development and commercialization of linaclotide in all other territories worldwide.

LINZESS Important Safety Information

INDICATIONS AND USAGE

LINZESS® (linaclotide) is indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients 7 years of age and older and for the treatment of chronic idiopathic constipation (CIC) in adults and for the treatment of functional constipation (FC) in children and adolescents 6 to 17 years of age.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE

LINZESS is contraindicated in patients less than 2 years of age. In nonclinical studies in neonatal mice, administration of a single, clinically relevant adult oral dose of linaclotide caused deaths due to dehydration.

Contraindications

  • LINZESS is contraindicated in patients less than 2 years of age due to the risk of serious dehydration.

  • LINZESS is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

Warnings and Precautions

  • LINZESS is contraindicated in patients less than 2 years of age. In neonatal mice, linaclotide increased fluid secretion as a consequence of age-dependent elevated guanylate cyclase (GC-C) agonism, which was associated with increased mortality within the first 24 hours due to dehydration. There was no age dependent trend in GC-C intestinal expression in a clinical study of children 2 to less than 18 years of age; however, there are insufficient data available on GC-C intestinal expression in children less than 2 years of age to assess the risk of developing diarrhea and its potentially serious consequences in these patients.

Diarrhea

  • In adults, diarrhea was the most common adverse reaction in LINZESS-treated patients in the pooled IBS-C and CIC double-blind placebo-controlled trials. The incidence of diarrhea was similar in the IBS-C and CIC populations. Severe diarrhea was reported in 2% of 145 mcg and 290 mcg LINZESS-treated patients and in <1% of 72 mcg LINZESS-treated CIC patients.

  • In pediatric patients, diarrhea was also the most common adverse reaction of LINZESS-treated patients in IBS-C and FC clinical trials. In two double-blind trials, diarrhea was reported in 4% of pediatric patients 6 to 17 years of age with FC treated with LINZESS 72 mcg once daily, and 7% and 8% of pediatric patients 7 to 17 years of age with IBS-C treated with LINZESS 145 mcg and 290 mcg once daily, respectively. In clinical trials, severe diarrhea was reported in one pediatric patient with FC treated with LINZESS 72 mcg once daily and in one pediatric patient with IBS-C treated with LINZESS at a dosage higher than the recommended 145 mcg once daily dosage for IBS-C.

Common Adverse Reactions (incidence ≥2% and greater than placebo)

  • In IBS-C or CIC adult patients: diarrhea, abdominal pain, flatulence and abdominal distension.

  • Most common adverse reaction reported in pediatric patients with FC or IBS-C is diarrhea.

Please see full Prescribing Information including Boxed Warning: https://www.rxabbvie.com/pdf/linzess_pi.pdf

LINZESS® and CONSTELLA® are registered trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to in this press release are the property of their respective owners. All rights reserved.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for the treatment of irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland.

We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on X and on LinkedIn.

About DDW

Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about Ironwood’s LANDMARK survey presentation; presentation of long-term safety and tolerability data from the apraglutide clinical program in adults with SBS who are dependent on PS and key findings from its Phase 3 open-label safety extension study of linaclotide in pediatric patients aged 2–5 years with FC, as well as analyses in adults with IBS-C and CIC; and the estimated adult population who suffer from SBS-IF in the U.S., Europe and Japan. These forward-looking statements speak only as of the date of this press release, and Ironwood undertakes no obligation to update these forward-looking statements. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include those related to the effectiveness of development and commercialization efforts by us and our partners; preclinical and clinical development, manufacturing and formulation development of linaclotide, apraglutide, and our other product candidates; the risk of uncertainty relating to pricing and reimbursement policies in the U.S., which, if not favorable for our products, could hinder or prevent our products’ commercial success; the risk that clinical programs and studies, including for linaclotide pediatric programs and apraglutide, may not progress or develop as anticipated, including that studies are delayed or discontinued for any reason, such as safety, tolerability, enrollment, manufacturing, economic or other reasons; the risk that findings from our completed nonclinical studies and clinical trials may not be replicated in later trials and earlier-stage clinical trials may not be predictive of the results we may obtain in later-stage clinical trials or of the likelihood of regulatory approval; the risk that apraglutide will not be approved by the FDA or other regulatory agencies; the risk of competition or that new products may emerge that provide different or better alternatives for treatment of the conditions that our products are approved to treat; the risk that we are unable to execute on our strategy to in-license externally developed products or product candidates; the risk that we are unable to successfully partner with other companies to develop and commercialize products or product candidates; the risk that healthcare reform and other governmental and private payor initiatives may have an adverse effect upon or prevent our products’ or product candidates’ commercial success; the efficacy, safety and tolerability of linaclotide and our product candidates; the risk that the commercial and therapeutic opportunities for LINZESS, apraglutide or our other product candidates are not as we expect; decisions by regulatory and judicial authorities; the risk we may never get additional patent protection for linaclotide, apraglutide and other product candidates, that patents for linaclotide, apraglutide or other products may not provide adequate protection from competition, or that we are not able to successfully protect such patents; the risk that we are unable to manage our expenses or cash use, or are unable to commercialize our products as expected; the risk that the development of any of our linaclotide pediatric programs and/or apraglutide is not successful or that any of our product candidates does not receive regulatory approval or is not successfully commercialized; outcomes in legal proceedings to protect or enforce the patents relating to our products and product candidates, including abbreviated new drug application litigation; the risk that financial and operating results may differ from our projections; developments in the intellectual property landscape; challenges from and rights of competitors or potential competitors; the risk that our planned investments do not have the anticipated effect on our company revenues; developments in accounting guidance or practice; Ironwood’s or AbbVie’s accounting practices, including reporting and settlement practices as between Ironwood and AbbVie; the risk that our indebtedness could adversely affect our financial condition or restrict our future operations; and the risks listed under the heading “Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2025, and in our subsequent Securities and Exchange Commission filings.

Company Contact:

Greg Martini

Chief Financial Officer

[email protected]

Investors:

Precision AQ (formerly Stern Investor Relations)

Stephanie Ascher

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Health Clinical Trials Research Pharmaceutical Science Biotechnology

MEDIA:

Logo
Logo

Ocugen to Present at April 2026 Investor and Industry Conferences

MALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at Oppenheimer’s 3rd Annual Innovation on the Island Biotech Summit from April 27-29, 2026 in Rio Grande, Puerto Rico; and Abhi Gupta, MBA, Executive Vice President, Commercial and Business Development at Ocugen will present at the 2026 Cell & Gene Meeting on the Mediterranean being held April 28-30, 2026 in Rome, Italy.

“I look forward to sharing our story with new audiences and building enthusiasm for why now is the time to get to know Ocugen,” said Dr. Musunuri. “Our gene-agnostic approach to addressing all mutations related to major blindness diseases has the potential to be first-in-class—disrupting existing treatment paradigms and bringing gene therapy to the masses. With our planned BLA submission for OCU400 beginning later this year, commercialization is within reach.”

Innovation on the Island will include panels, company presentations, and networking opportunities. Biotech investors based in Puerto Rico as well as the continental United States will be in attendance.

The Cell & Gene Meeting on the Med brings together the ATMP community from Europe and beyond and covers a wide range of commercialization topics from market access and regulatory issues to manufacturing and financing. Ocugen is a proud member and collaborator with the meeting’s organizer, the Alliance for Regenerative Medicine.

Details on the Company presentations are as follows:

Innovation on the Island

Date: Tuesday, April 28, 2026
Time: 8:20 a.m. AST
Location: Four Seasons Bahia Beach Resort

Meeting on the Med

Date: Tuesday, April 28, 2026
Time: 4:30 p.m. CEST
Location: Rome Cavalieri, Salone dei Cavalieri, Section 1

Executive Leadership looks forward to providing updates on Ocugen’s novel modifier gene therapy platform, including near-term key catalysts, during one-on-one opportunities at these important conferences.

About Ocugen, Inc.

Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late-stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
AVP, Head of Communications
[email protected]



Altisource Announces First Quarter 2026 Financial Results

LUXEMBOURG, April 23, 2026 (GLOBE NEWSWIRE) — Altisource Portfolio Solutions S.A. (“Altisource” or the “Company”) (NASDAQ: ASPS), a leading provider and marketplace for the real estate and mortgage industries, today reported financial results for the first quarter 2026.

“We are off to a strong start in 2026. For the quarter, we grew Service revenue by 10%, and pretax GAAP earnings by $4.9 million and cash provided by operating activities by $9.4 million, compared to the first quarter of 2025, primarily from sales wins and lower debt related interest and transaction costs. More importantly, we are seeing strength in both business segments. The Origination segment grew first quarter Service revenue by 71% and Adjusted EBITDA(1) by 166% compared to last year, primarily from sales wins and a stronger origination market. The Servicer and Real Estate segment is positioned extremely well with Hubzu inventory at 17,200 homes as of the end of the first quarter and exciting first quarter sales wins in the Title and Foreclosure Trustee businesses,” said William B. Shepro, Chairman and Chief Executive Officer.

First Quarter
2026
Highlights

(2)

Company, Corporate and Financial:

  • First quarter Service revenue of $45.1 million was $4.2 million, or 10%, higher than the same quarter of 2025
  • First quarter Income before income taxes and non-controlling interests of $0.4 million was a $4.9 million improvement compared to the same quarter of 2025
  • First quarter Net loss attributable to Altisource of $0.6 million was a $4.7 million improvement compared to the same quarter of 2025
  • First quarter Diluted loss per share of $(0.06) was a $0.68 improvement compared to the same quarter of 2025
  • First quarter Adjusted diluted earnings per share(1) of $0.19 was a $0.21 improvement compared to the same quarter of 2025
  • First quarter Adjusted earnings before interest, tax, depreciation and amortization (“Adjusted EBITDA”)(1) of $4.4 million was $(0.8) million, or (15)% lower than the same quarter of 2025
  • First quarter Adjusted EBITDA(1) margin of 10% was lower than the 13% Adjusted EBITDA(1) margin in the same quarter of 2025 largely due to revenue mix
  • First quarter Cash provided by operating activities of $4.5 million was a $9.4 million improvement, compared to the same quarter of 2025, and we ended the quarter with $30.3 million of cash and cash equivalents

Business and Industry:

  • Adjusted EBITDA(1) in the Servicer and Real Estate and Origination segments (together “Business Segments”) was $12.0 million, or 26.7% of Service revenue, compared to $12.5 million, or 30.5% of Service revenue, in the same quarter of 2025 primarily due to a change in revenue mix.
  • Generated sales wins which we estimate represent potential annualized service revenue on a stabilized basis of $12.4 million for the Servicer and Real Estate segment and $4.7 million for the Origination segment
  • Driven by recent sales wins, total Hubzu inventory has more than tripled since September 30, 2025
  (in thousands)   September 30,
2025
  December 31,
2025
  March 31,

2026
 
  Foreclosure Auction Inventory(5)   4.0   4.9   14.0  
  REO Inventory – Customers other than Rithm   0.7   1.4   2.3  
  REO Inventory – Rithm   1.0   1.0   0.9  
  Total Hubzu Inventory   5.7   7.3   17.2  
  • Ended the quarter with a weighted average sales pipeline between $25.7 million and $32.1 million of potential estimated annual revenue on a stabilized basis based upon forecasted probability of closing (comprising of between $10.4 million and $13.0 million in the Servicer and Real Estate segment and between $15.3 million and $19.1 million in the Origination segment)
  • Industrywide foreclosure initiations were 5% higher for the two months ended February 28, 2026 compared to the same period in 2025 (although still 14% lower than the same pre-COVID-19 period in 2019)(3)
  • Industrywide foreclosure sales were 27% higher for the two months ended February 28, 2026 compared to the same period in 2025 (although still 42% lower than the same pre-COVID-19 period in 2019)(3)
  • Industrywide mortgage origination volume increased by 42% for the three months ended March 31, 2026 compared to the same period in 2025, comprised of a 19% increase in purchase origination and a 91% increase in refinancing origination(4)

First Quarter
2026
Financial Results

  • Service revenue of $45.1 million
  • Income from operations of $1.7 million
  • Income before income taxes and non-controlling interests of $0.4 million
  • Net loss attributable to Altisource of $(0.6) million
  • Adjusted EBITDA(1) of $4.4 million
  • Diluted loss per share of $(0.06)
  • Adjusted diluted earnings per share(1) of $0.19

First Quarter
2026
Results Compared to the
First Quarter
2025
(unaudited):

(in thousands, except per share data) First
Quarter
2026
  First
Quarter
2025
  %
Change
Service revenue $ 45,089     $ 40,895     10  
Revenue   47,584       43,439     10  
Gross profit   13,111       13,325     (2 )
Income from operations   1,725       3,245     (47 )
Adjusted operating income(1)   4,411       5,199     (15 )
Income (loss) before income taxes and non-controlling interests   356       (4,529 )   108  
Pretax income (loss) attributable to Altisource(1)   252       (4,602 )   105  
Adjusted pretax income attributable to Altisource(1)   2,938       332     N/M  
Adjusted EBITDA(1)   4,449       5,262     (15 )
Net loss attributable to Altisource   (635 )     (5,344 )   88  
Adjusted net income (loss) attributable to Altisource(1)   2,136       (144 )   N/M  
Diluted loss per share   (0.06 )     (0.74 )   92  
Adjusted diluted earnings (loss) per share(1)   0.19       (0.02 )   N/M  
Net cash provided by (used in) operating activities   4,453       (4,972 )   190  
Net cash provided by (used in) operating activities less additions to premises and equipment(1)   4,315       (4,997 )   186  
           
Margins:          
Gross profit / service revenue   29 %     33 %    
Adjusted EBITDA(1) / service revenue   10 %     13 %    

______________________
N/M — not meaningful.
         

First quarter 2025 loss before income taxes and non-controlling interests includes $3.0 million of Debt Exchange Transaction expenses (no comparative amount for the first quarter 2026).
________________________
(1)  This is a non-GAAP measure that is defined and reconciled to the corresponding GAAP measure herein
(2) Applies to the first quarter 2026 unless otherwise indicated
(3) Based on data from ICE’s Mortgage Monitor and First Look reports with data through February 2026
(4) Based on estimated number of loans originated as reported by the Mortgage Bankers Association’s Mortgage Finance Forecast dated March 23, 2026
(5)  Altisource does not provide foreclosure auction services to Rithm



Forward-Looking Statements

This press release contains forward-looking statements that involve a number of risks and uncertainties. These forward-looking statements include all statements that are not historical fact, including statements that relate to, among other things, future events or our future financial / operating performance or financial condition. These statements may be identified by words such as “anticipate,” “intend,” “expect,” “may,” “could,” “should,” “would,” “will,” “plan,” “estimate,” “seek,” “believe,” “potential” or “continue” or the negative of these terms and comparable terminology. Such statements are based on expectations as to the future and are not statements of historical fact. Furthermore, forward-looking statements are not guarantees of future performance and involve a number of assumptions, risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ materially from those suggested by the forward-looking statements include, but are not limited to, the risks discussed in Item 1A of Part I “Risk Factors” in our Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 4, 2026. We caution you not to place undue reliance on these forward-looking statements which reflect our view only as of the date of this report. We are under no obligation (and expressly disclaim any obligation) to update or alter any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or change in events, conditions or circumstances on which any such statement is based. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, risks related to customer concentration, impacts to default related referrals occasioned by government, investor or servicer actions, the use and success of our products and services, our ability to retain existing customers and attract new customers and the potential for expansion or changes in our customer relationships, technology disruptions, our compliance with applicable data requirements, our use of third party vendors and contractors, our ability to effectively manage potential conflicts of interest, macro-economic and industry specific conditions, our ability to effectively manage our regulatory and contractual obligations, the adequacy of our financial resources, including our sources of liquidity and ability to repay borrowings and comply with our debt agreements, including the financial and other covenants contained therein, as well as Altisource’s ability to retain key executives or employees, behavior of customers, suppliers and/or competitors, technological developments, governmental regulations, taxes and policies. The financial projections and scenarios contained in this press release are expressly qualified as forward-looking statements and, as with other forward-looking statements, should not be unduly relied upon. We undertake no obligation to update these statements, scenarios and projections as a result of a change in circumstances, new information or future events, except as required by law.

Webcast

Altisource will host a webcast at 08:30 a.m. EDT today to discuss our first quarter. A link to the live audio webcast will be available on Altisource’s website in the Investor Relations section. Those who want to listen to the call should go to the website at least fifteen minutes prior to the call to register, download and install any necessary audio software. A replay of the conference call will be available via the website approximately two hours after the conclusion of the call and will remain available for approximately 30 days.

About Altisource
®

Altisource Portfolio Solutions S.A. is an integrated service provider and marketplace for the real estate and mortgage industries. Combining operational excellence with a suite of innovative services and technologies, Altisource helps solve the demands of the ever-changing markets it serves. Additional information is available at www.altisource.com

FOR FURTHER INFORMATION CONTACT:

Michelle D. Esterman
Chief Financial Officer
T: (770) 612-7007
E: [email protected] 

 
ALTISOURCE PORTFOLIO SOLUTIONS S.A.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except per share data)
(unaudited)
 
    Three months ended

March 31,
    2026
  2025
         
Service revenue   $ 45,089     $ 40,895  
Reimbursable expenses     2,391       2,471  
Non-controlling interests     104       73  
Total revenue     47,584       43,439  
Cost of revenue     34,473       30,114  
Gross profit     13,111       13,325  
Selling, general and administrative expenses     11,386       10,080  
Income from operations     1,725       3,245  
Other income (expense), net:        
Interest expense     (2,109 )     (4,938 )
Debt exchange transaction expenses           (2,980 )
Other income (expense), net     740       144  
Total other income (expense), net     (1,369 )     (7,774 )
         
Income (loss) before income taxes and non-controlling interests     356       (4,529 )
Income tax provision     (887 )     (742 )
         
Net loss             (531 )             (5,271 )
Net income attributable to non-controlling interests             (104 )             (73 )
         
Net loss attributable to Altisource   $         (635 )   $         (5,344 )
         
Loss per share:        
Basic   $         (0.06 )   $         (0.74 )
Diluted   $         (0.06 )   $         (0.74 )
         
Weighted average shares outstanding:        
Basic     11,111       7,265  
Diluted     11,111       7,265  
         
Comprehensive loss:        
Net loss   $         (531 )   $         (5,271 )
Comprehensive income attributable to non-controlling interests             (104 )             (73 )
         
Comprehensive loss attributable to Altisource   $         (635 )   $         (5,344 )

 
ALTISOURCE PORTFOLIO SOLUTIONS S.A.
CONSOLIDATED BALANCE SHEETS
(in thousands, except for per share data)
(unaudited)
 
  March 31,

2026
  December 31,

2025
       
ASSETS
Current assets:      
Cash and cash equivalents $ 30,340     $ 26,603  
Accounts receivable, net of allowance for credit losses of $1,855 and $2,492, respectively   20,691       17,984  
Prepaid expenses and other current assets   7,799       9,690  
Total current assets   58,830       54,277  
       
Premises and equipment, net   333       253  
Right-of-use assets under operating leases   943       1,117  
Goodwill   55,960       55,960  
Intangible assets, net   15,661       17,085  
Deferred tax assets, net   6,246       6,342  
Other assets   4,181       4,767  
       
Total assets $ 142,154     $ 139,801  
       
LIABILITIES AND DEFICIT
Current liabilities:      
Accounts payable and accrued expenses $ 43,725     $ 39,595  
Current portion of long-term debt   1,225       1,225  
Deferred revenue   3,986       3,440  
Other current liabilities   2,055       2,805  
Total current liabilities   50,991       47,065  
       
Long-term debt   188,526       189,861  
Deferred tax liabilities, net   8,600       8,641  
Other non-current liabilities   3,679       3,697  
       
Commitments, contingencies and regulatory matters      
       
Deficit:      
Common stock ($0.01 par value; 250,000 shares authorized, 11,279 issued and outstanding as of March 31, 2026; 11,021 issued and 10,994 outstanding as of December 31, 2025)   113       110  
Additional paid-in capital   257,765       257,359  
Accumulated deficit   (368,337 )     (363,735 )
Treasury stock, at cost (27 shares as of December 31, 2025)         (3,948 )
Altisource deficit   (110,459 )     (110,214 )
       
Non-controlling interests   817       751  
Total deficit   (109,642 )     (109,463 )
       
Total liabilities and deficit $ 142,154     $ 139,801  

   
ALTISOURCE PORTFOLIO SOLUTIONS S.A.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
   
  Three months ended

March 31,
  2026
  2025
       
Cash flows from operating activities:      
Net loss $ (531 )   $ (5,271 )
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:      
Depreciation and amortization   58       185  
Amortization of right-of-use assets under operating leases   377       185  
Amortization of intangible assets   1,424       1,270  
Share-based compensation expense   1,193       1,094  
Bad debt expense   74       (137 )
Amortization of debt premium   (1,185 )     (766 )
Amortization of debt discount   102       641  
Amortization of debt issuance costs   54       407  
Deferred income taxes   (41 )     46  
Changes in operating assets and liabilities:      
Accounts receivable   (2,781 )     (3,001 )
Prepaid expenses and other current assets   1,899       336  
Other assets   105       (9 )
Accounts payable and accrued expenses   4,130       415  
Current and non-current operating lease liabilities   (399 )     (195 )
Other current and non-current liabilities   (26 )     (172 )
Net cash provided by (used in) operating activities   4,453       (4,972 )
       
Cash flows from investing activities:      
Additions to premises and equipment   (138 )     (25 )
Net cash used in investing activities   (138 )     (25 )
       
Cash flows from financing activities:      
Proceeds from the Super Senior Facility         11,250  
Debt issuance costs         (1,749 )
Repayments of long-term debt   (306 )      
Equity issuance costs         (3,191 )
Distributions to non-controlling interests   (38 )     (2 )
Payments of tax withholding on vesting of restricted share units and restricted shares   (803 )     (318 )
Net cash (used in) provided by financing activities   (1,147 )     5,990  
       
Net increase in cash, cash equivalents and restricted cash   3,168       993  
Cash, cash equivalents and restricted cash at the beginning of the period   30,493       32,700  
       
Cash, cash equivalents and restricted cash at the end of the period $ 33,661     $ 33,693  
       
  Three months ended
March 31,
  2025
  2024
       
Supplemental cash flow information:      
Interest paid $ 3,128     $ 4,535  
Income taxes paid, net   352       96  
Acquisition of right-of-use assets with operating lease liabilities   206       26  
Reduction of right-of-use assets from operating lease modifications or reassessments   (4 )     (162 )
       
Non-cash investing and financing activities:      
Equity issued in exchange for debt reduction         45,370  

ALTISOURCE PORTFOLIO SOLUTIONS S.A.

NON-GAAP MEASURES


(in thousands, except per share data)


(unaudited)

Adjusted operating income, pretax income (loss) attributable to Altisource, adjusted pretax income attributable to Altisource, adjusted net income (loss) attributable to Altisource, adjusted diluted earnings (loss) per share, Net cash provided by (used in) operating activities less additions to premises and equipment, Adjusted EBITDA, Business Segments Adjusted EBITDA and net debt, which are presented elsewhere in this earnings release, are non-GAAP measures used by management, existing shareholders, potential shareholders and other users of our financial information to measure Altisource’s performance and do not purport to be alternatives to income from operations, income (loss) before income taxes and non-controlling interests, net loss attributable to Altisource, diluted loss per share, Net cash provided by (used in) operating activities and long-term debt, including current portion, as measures of Altisource’s performance. We believe these measures are useful to management, existing shareholders, potential shareholders and other users of our financial information in evaluating operating profitability and cash flow generation more on the basis of continuing cost and cash flows as they exclude amortization expense related to acquisitions that occurred in prior periods and non-cash share-based compensation, as well as the effect of more significant non-operational items from earnings, cash flows from operating activities and long-term debt net of cash on-hand. We believe these measures are also useful in evaluating the effectiveness of our operations and underlying business trends in a manner that is consistent with management’s evaluation of business performance. Furthermore, we believe the exclusion of more significant non-operational items enables comparability to prior period performance and trend analysis. Specifically, management uses adjusted net income (loss) attributable to Altisource to measure the on-going after tax performance of the Company because the measure adjusts for the after tax impact of more significant non-recurring items, amortization expense relating to prior acquisitions (some of which fluctuates with revenue from certain customers and some of which is amortized on a straight-line basis) and non-cash share-based compensation expense which can fluctuate based on vesting schedules, grant date timing and the value attributable to awards. We believe adjusted net income (loss) attributable to Altisource is useful to existing shareholders, potential shareholders and other users of our financial information because it provides an after-tax measure of Altisource’s on-going performance that enables these users to perform trend analysis using comparable data. Management uses adjusted diluted earnings (loss) per share to further evaluate adjusted net income (loss) attributable to Altisource while taking into account changes in the number of diluted shares over the comparable periods. We believe adjusted diluted earnings (loss) per share is useful to existing shareholders, potential shareholders and other users of our financial information because it also enables these users to evaluate adjusted net income (loss) attributable to Altisource on a per share basis. Management uses Adjusted EBITDA to measure the Company’s overall performance and Business Segments Adjusted EBITDA to measure the segments overall performance (with the adjustments discussed earlier with regard to adjusted net income (loss) attributable to Altisource) without regard to its capitalization (debt vs. equity) or its income taxes and to perform trend analysis of the Company’s performance over time. Our effective income tax rate can vary based on the jurisdictional mix of our income. Additionally, as the Company’s capital expenditures have significantly declined over time, it provides a measure for management to evaluate the Company’s performance without regard to prior capital expenditures. Management also uses Adjusted EBITDA as one of the measures in determining bonus compensation for certain employees. We believe Adjusted EBITDA and Business Segments Adjusted EBITDA are useful to existing shareholders, potential shareholders and other users of our financial information for the same reasons that management finds the measure useful. Management uses net debt in evaluating the amount of debt the Company has that is in excess of cash and cash equivalents. We believe net debt is useful to existing shareholders, potential shareholders and other users of our financial information for the same reasons management finds the measure useful.

Altisource operates in several countries, including Luxembourg, India, the United States and Uruguay. The Company has differing effective tax rates in each country and these rates may change from year to year. In determining the tax effects related to the adjustments in calculating adjusted net loss attributable to Altisource and adjusted diluted earnings (loss) per share, we use the tax rate in the country in which the adjustment applies or, if the adjustment is recognized in more than one country, we separate the adjustment by country, apply the relevant tax rate for each country to the applicable adjustment, and then sum the result to arrive at the total adjustment, net of tax. In 2019, the Company recognized a full valuation allowance on its net deferred tax assets in Luxembourg. Accordingly, for 2026 and 2025, the Company has an effective tax rate of close to 0% in Luxembourg.

It is management’s intent to provide non-GAAP financial information to enhance the understanding of Altisource’s GAAP financial information, and it should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. Each non-GAAP financial measure is presented along with the corresponding GAAP measure so as not to imply that more emphasis should be placed on the non-GAAP measure. The non-GAAP financial information presented may be determined or calculated differently by other companies. The non-GAAP financial information should not be unduly relied upon.

Adjusted operating income is calculated by removing intangible asset amortization expense, share-based compensation expense, cost of cost savings initiatives and other from income from operations. Pretax income (loss) attributable to Altisource is calculated by removing non-controlling interests from income (loss) before income taxes and non-controlling interests. Adjusted pretax income attributable to Altisource is calculated by removing non-controlling interests, intangible asset amortization expense, share-based compensation expense, cost of cost savings initiatives and other and debt exchange transaction expenses from income (loss) before income taxes and non-controlling interests. Adjusted net income (loss) attributable to Altisource is calculated by removing intangible asset amortization expense (net of tax), share-based compensation expense (net of tax), cost of cost savings initiatives and other (net of tax), debt exchange transaction expenses (net of tax) and certain income tax related items from net loss attributable to Altisource. Adjusted diluted earnings (loss) per share is calculated by dividing net loss attributable to Altisource after removing intangible asset amortization expense (net of tax), share-based compensation expense (net of tax), cost of cost savings initiatives and other (net of tax), debt exchange transaction expenses (net of tax) and certain income tax related items by the weighted average number of diluted shares. Net cash provided by (used in) operating activities less additions to premises and equipment is calculated by removing additions to premises and equipment from Net cash provided by (used in) operating activities. Adjusted EBITDA is calculated by removing the income tax provision, interest expense (net of interest income), depreciation and amortization, intangible asset amortization expense, share-based compensation expense, cost of cost savings initiatives and other and debt exchange transaction expenses from net loss attributable to Altisource. Business Segments Adjusted EBITDA is calculated by removing non-controlling interests, interest expense (net of interest income), depreciation and amortization, intangible asset amortization expense, share-based compensation expense, cost of cost savings initiatives and other from income before income taxes and non-controlling interests. Net debt is calculated as long-term debt, including current portion, minus cash and cash equivalents.

Reconciliations of the non-GAAP measures to the corresponding GAAP measures are as follows:

    Three months ended

March 31,
    2026
  2025
         
Income from operations   $ 1,725     $ 3,245  
         
Intangible asset amortization expense     1,424       1,270  
Share-based compensation expense     1,193       1,094  
Cost of cost savings initiatives and other     69       (410 )
         
Adjusted operating income   $ 4,411     $ 5,199  
         
Income (loss) before income taxes and non-controlling interests   $ 356     $ (4,529 )
         
Non-controlling interests     (104 )     (73 )
Pretax income (loss) attributable to Altisource     252       (4,602 )
Intangible asset amortization expense     1,424       1,270  
Share-based compensation expense     1,193       1,094  
Cost of cost savings initiatives and other     69       (410 )
Debt exchange transaction expenses           2,980  
         
Adjusted pretax income attributable to Altisource   $ 2,938     $ 332  
         
Net loss attributable to Altisource   $ (635 )   $ (5,344 )
         
Income tax provision     887       742  
Interest expense (net of interest income)     1,453       4,745  
Depreciation and amortization     58       185  
Intangible asset amortization expense     1,424       1,270  
Share-based compensation expense     1,193       1,094  
Cost of cost savings initiatives and other     69       (410 )
Debt exchange transaction expenses           2,980  
         
Adjusted EBITDA   $ 4,449     $ 5,262  
         
Business Segments:        
Income before income taxes and non-controlling interests   $ 10,491     $ 10,856  
         
Non-controlling interests     (104 )     (73 )
Depreciation and amortization     49       78  
Intangible asset amortization expense     1,424       1,270  
Share-based compensation expense     133       279  
Cost of cost savings initiatives and other     37       29  
Interest expense (net of interest income)     8       27  
         
Business Segments Adjusted EBITDA   $ 12,038     $ 12,466  
         
Corporate and Others:        
Loss before income taxes and non-controlling interests   $ (10,135 )   $ (15,385 )
         
Depreciation and amortization     9       107  
Share-based compensation expense     1,060       815  
Cost of cost savings initiatives and other     32       (439 )
Debt exchange transaction expenses           2,980  
Interest expense (net of interest income)     1,445       4,718  
         
Corporate and Others Adjusted EBITDA   $ (7,589 )   $ (7,204 )
         
Net loss attributable to Altisource   $ (635 )   $ (5,344 )
         
Intangible asset amortization expense, net of tax     1,391       1,270  
Share-based compensation expense, net of tax     1,064       953  
Cost of cost savings initiatives and other, net of tax     60       (396 )
Debt exchange transaction expenses, net of tax           2,980  
Certain income tax related items     257       393  
         
Adjusted net income (loss) attributable to Altisource   $ 2,137     $ (144 )
         
Diluted loss per share   $ (0.06 )   $ (0.74 )
         
Intangible asset amortization expense, net of tax, per diluted share     0.13       0.17  
Share-based compensation expense, net of tax, per diluted share     0.10       0.13  
Cost of cost savings initiatives and other, net of tax, per diluted share     0.01       (0.05 )
Debt exchange transaction expenses, per diluted share           0.41  
Certain income tax related items, per diluted share     0.02       0.05  
         
Adjusted diluted earnings (loss) per share   $ 0.19     $ (0.02 )
         
Calculation of the per share impact of intangible asset amortization expense, net of tax        
Intangible asset amortization expense   $ 1,424     $ 1,270  
Tax benefit from intangible asset amortization     (33 )      
Intangible asset amortization expense, net of tax     1,391       1,270  
Diluted share count     11,111       7,265  
         
Intangible asset amortization expense, net of tax, per diluted share   $ 0.13     $ 0.17  
         
Calculation of the per share impact of share-based compensation expense, net of tax        
Share-based compensation expense   $ 1,193     $ 1,094  
Tax benefit from share-based compensation expense     (129 )     (141 )
Share-based compensation expense, net of tax     1,064       953  
Diluted share count     11,111       7,265  
         
Share-based compensation expense, net of tax, per diluted share   $ 0.10     $ 0.13  
         
Calculation of the impact of debt exchange transaction expenses, net of tax        
Debt exchange transaction expenses   $     $ 2,980  
Tax benefit from share-based compensation expense            
Debt exchange transaction expenses, net of tax           2,980  
Diluted share count     11,111       7,265  
         
Debt exchange transaction expenses, net of tax per diluted share   $     $ 0.41  
         
Calculation of the per share impact of cost of cost savings initiatives and other, net of tax        
Cost of cost savings initiatives and other   $ 69     $ (410 )
Tax (benefit) provision from cost of cost savings initiatives and other     (10 )     14  
Cost of cost savings initiatives and other, net of tax     60       (396 )
Diluted share count     11,111       7,265  
         
Cost of cost savings initiatives and other, net of tax, per diluted share   $ 0.01     $ (0.05 )
         
Calculation of the per share impact of certain income tax related items resulting from:        
Foreign income tax reserves / other   $ 257     $ 393  
Certain income tax related items     257       393  
Diluted share count     11,111       7,265  
         
Certain income tax related items, per diluted share   $ 0.02     $ 0.05  
         
Net cash provided by (used in) operating activities   $ 4,453     $ (4,972 )
Less: additions to premises and equipment     (138 )     (25 )
         
Net cash provided by (used in) operating activities less additions to premises and equipment   $ 4,315     $ (4,997 )

  March 31, 2026
   
Senior secured term loans $ 158,900  
Super senior term loan   12,360  
Less: Cash and cash equivalents   (30,340 )
   
Net debt $ 140,920  

______________________________________________
Note: Amounts may not add to the total due to rounding.



Nasdaq Announces Increase in Quarterly Dividend to $0.31 Per Share

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) — The Board of Directors of Nasdaq, Inc. (Nasdaq: NDAQ) has declared a regular quarterly dividend of $0.31 per share on the company’s outstanding common stock. The dividend is payable on June 26, 2026 to shareholders of record at the close of business on June 12, 2026. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors.

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading technology platform that powers the world’s economies. We architect the infrastructure of the world’s most modern markets, power the innovation economy, and build trust in the financial system. We empower economic opportunity by designing and deploying advanced technology, data, and intelligence solutions that enable our clients to capture opportunities, navigate risk, and strengthen resilience. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com.

Cautionary Note Regarding Forward-Looking Statements

Information set forth in this communication contains forward-looking statements that involve a number of risks and uncertainties. Nasdaq cautions readers that any forward-looking information is not a guarantee of future performance, and that actual results could differ materially from those contained in the forward-looking information. Such forward-looking statements include, but are not limited to, information regarding our dividend program and future payment obligations. Forward-looking statements involve a number of risks, uncertainties, or other factors beyond Nasdaq’s control. These factors include, but are not limited to, Nasdaq’s ability to implement its strategic initiatives, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk, U.S. and global competition, and other factors detailed in Nasdaq’s filings with the U.S. Securities and Exchange Commission, including its annual reports on Form 10-K and quarterly reports on Form 10-Q which are available on Nasdaq’s investor relations website at 

http://ir.nasdaq.com

 and the SEC’s website at 

www.sec.gov

. Nasdaq undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Media Relations Contact:

David Lurie
+1.914.538.0533
[email protected]

Investor Relations Contact:

Ato Garrett
+1.212.401.8737
[email protected]

-NDAQF-



ConnectOne Bancorp, Inc. Reports First Quarter 2026 Results

NET INTEREST MARGIN WIDENS BY 12 BASIS POINTS; TREND CONFIRMED
10% ANNUALIZED LOAN GROWTH
OPERATING PERFORMANCE ACCELERATES
TANGIBLE BOOK VALUE PER SHARE INCREASES
8.3% INCREASE IN COMMON DIVIDEND PER SHARE DECLARED

ENGLEWOOD CLIFFS, N.J., April 23, 2026 (GLOBE NEWSWIRE) — ConnectOne Bancorp, Inc. (Nasdaq: CNOB) (the “Company” or “ConnectOne”), parent company of ConnectOne Bank (the “Bank”), today reported net income available to common stockholders of $36.3 million for the first quarter of 2026 compared with $38.0 million for the fourth quarter of 2025 and $18.7 million for the first quarter of 2025. Diluted earnings per share were $0.72 for the first quarter of 2026 compared with $0.75 for the fourth quarter of 2025 and $0.49 for the first quarter of 2025. Return on average assets was 1.10%, 1.12% and 0.84% for the three months ended March 31, 2026, December 31, 2025 and March 31, 2025, respectively. Return on average tangible common equity was 12.89%, 13.66% and 8.25% for the three months ended March 31, 2026, December 31, 2025 and March 31, 2025, respectively.

Pre-provision net operating revenue (“Operating PPNR”) as a percentage of average assets was 1.81%, 1.75% and 1.34% for the quarters ending March 31, 2026, December 31, 2025 and March 31, 2025, respectively. The sequential increase in Operating PPNR was primarily due to a $2.2 million increase in net interest income, partially offset by a $0.9 million increase in operating expenses. Operating net income available to common stockholders was $39.6 million for the first quarter of 2026, $42.0 million for the fourth quarter of 2025 and $19.7 million for the first quarter of 2025. Operating diluted earnings per share were $0.79 for the first quarter of 2026, $0.83 for the fourth quarter of 2025 and $0.51 for the first quarter of 2025. Operating return on average assets was 1.19%, 1.24% and 0.88% for the three months ended March 31, 2026, December 31, 2025 and March 31, 2025, respectively. Operating return on average tangible common equity was 13.35%, 14.27% and 8.59% for the three months ended March 31, 2026, December 31, 2025 and March 31, 2025, respectively. See supplemental tables for a complete reconciliation of GAAP earnings to operating earnings, and other non-GAAP measures.

The decrease in net income available to common stockholders during the first quarter of 2026 when compared to the fourth quarter of 2025 was primarily due to a $2.9 million increase in the provision for credit losses, a $0.9 million increase in noninterest expenses and a $0.9 million increase in income tax expense, which were partially offset by a $2.2 million increase in net interest income and a $0.8 million increase in noninterest income. The first quarter of 2026 included restructuring charges related to the merger with the First of Long Island Corporation (“FLIC”) of $2.0 million reflecting our ongoing commitment to streamlining operations and enhancing organizational efficiency. The increase in net income available to common stockholders and diluted earnings per share during the first quarter of 2026 when compared to the first quarter of 2025 was primarily due to a $43.0 million increase in net interest income and a $2.3 million increase in noninterest income, which was partially offset by an increase in noninterest expense of $18.6 million and an increase in income tax expense of $7.5 million. The variances from the first quarter of 2026 to the first quarter of 2025 were primarily due to the merger with FLIC.

“ConnectOne began 2026 with robust momentum, positioning us for what we expect to be a strong year,” commented Frank Sorrentino, ConnectOne’s Chairman and Chief Executive Officer. “Loans and deposits both grew sequentially at an annualized rate of approximately 10%, while our net interest margin expanded by 12 basis points. Accelerating portfolio loan yields are expected to support continued net interest margin expansion in the quarters ahead, even without further rate cuts.”

“Expenses remain well-controlled as we continue to leverage merger synergies and drive additional productivity gains through increasing use of AI workflow across the organization.” Mr. Sorrentino added, “During the first quarter, our strong retained earnings supported loan growth, share repurchases, and a 1.7% increase in tangible book value per share; we are now approximately one quarter away from returning to our pre-merger tangible book value per share of $24.16.”

“Our credit quality remained solid this quarter. Although 30-59 day delinquencies increased due to one isolated credit relationship, net charge-offs (excluding PCD loans) declined to just 8 basis points annualized, a recent low. The nonaccrual loan ratio also decreased, while criticized and classified asset metrics remained at historically low levels, underscoring our continued portfolio management strength.”

“Subsequent to quarter-end, noninterest income continued to build momentum, driven by accelerating SBA loan sale activity. We generated an additional $1.1 million in gains in April, and the pipeline remains robust.” Mr. Sorrentino concluded, “Looking ahead to the remainder of the year, we’re executing against our strategic priorities and remain well positioned to deliver long-term value for our shareholders in 2026 and beyond.”

Dividend Declarations

The Company announced that its Board of Directors declared an increased quarterly cash dividend on its common stock and declared a cash dividend on its outstanding preferred stock. A cash dividend on common stock of $0.195 per share, reflecting an increase of $0.015, or 8.3%, will be paid on June 1, 2026, to common stockholders of record on May 15, 2026. A dividend of $0.328125 per depositary share, representing a 1/40th interest in a share of the Company’s 5.25% Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock, Series A, will also be paid on June 1, 2026 to holders of record on May 15, 2026.

Operating Results

Fully taxable equivalent net interest income for the first quarter of 2026 was $110.0 million, an increase of $2.2 million, or 2.1%, from the fourth quarter of 2025, largely due to a 12 basis-point widening of the net interest margin to 3.39% from 3.27%. The margin benefited from an increase in the yield on interest-earning assets, primarily due to loan repricing, combined with a 12 basis-point decrease in the average costs of deposits, including noninterest-bearing deposits, and partially offset by an increased cost in borrowed funds.

Fully taxable equivalent net interest income for the first quarter of 2026 increased $43.4 million, or 65.2%, from the first quarter of 2025, due to a 46 basis-point widening of the net interest margin to 3.39% from 2.93%, and a 42.7% increase in average interest-earning assets. The increase in average interest-earning assets was primarily due to the merger with FLIC. The margin benefited from a 20 basis-point increase in the yield on interest-earning assets and a 49 basis-point decrease in the average costs of deposits, including noninterest-bearing deposits.

Noninterest income was $6.8 million in the first quarter of 2026, $6.0 million in the fourth quarter of 2025 and $4.5 million in the first quarter of 2025. The increase compared to the fourth quarter of 2025 was primarily due to a $1.0 million increase in net gains (losses) on equity securities. The increase compared to the first quarter of 2025 was primarily due to a $1.4 million increase in BOLI income and a $1.3 million increase in deposit, loan and other income, which was partially offset by a $0.4 million decrease in net gains (losses) on equity securities. The year-over-year increases in BOLI income and deposit, loan and other income were primarily due to the merger with FLIC. Extending this positive momentum into the second quarter, the Company realized an additional $1.1 million in SBA loan sale gains in April 2026.

Noninterest expenses were $57.9 million for the first quarter of 2026, $56.9 million for the fourth quarter of 2025 and $39.3 million for the first quarter of 2025. Excluding merger expenses and restructuring charges and branch closing expenses, noninterest expenses totaled $55.7 million in the first quarter of 2026, $55.2 million in the fourth quarter of 2025 and $38.0 million in the first quarter of 2025. The increase of $0.6 million during the first quarter of 2026 when compared to the fourth quarter of 2025 was primarily due to a $1.6 million increase in salaries and employee benefits, which was partially offset by a $0.4 million decrease in FDIC insurance expense and a $0.4 million decrease in amortization of core deposit intangible. The $17.8 million increase in noninterest expenses for the first quarter of 2026 when compared to the first quarter of 2025 was primarily due to a $10.2 million increase in salaries and employee benefits, a $2.7 million increase in occupancy and equipment expenses, a $2.6 million increase in amortization of core deposit intangibles, a $0.8 million increase in other expenses, a $0.7 million increase in professional and consulting expense, and a $0.6 million increase in information technology and communication expenses. The variances from the first quarter of 2026 to the first quarter of 2025 were primarily due to the merger with FLIC.

Income tax expense was $14.7 million for the first quarter of 2026, $13.9 million for the fourth quarter of 2025 and $7.2 million for the first quarter of 2025. The effective tax rates were 28.0%, 26.0% and 26.1% for the first quarter of 2026, fourth quarter of 2025 and first quarter of 2025, respectively. The increase in effective rates when compared to 2025 was primarily due to state and local apportionment factors associated with the FLIC merger. 

Asset Quality

The provision for credit losses was $5.2 million for the first quarter of 2026, $2.3 million for the fourth quarter of 2025 and $3.5 million for the first quarter of 2025. In each of the quarters presented, the provision for credit losses reflected net portfolio growth, charges related to individually evaluated loans, and changing macroeconomic forecasts and conditions. The current quarter’s provision was driven by higher loan growth and increased qualitative factors, which were partially offset by improved loss drivers within our quantitative CECL model reflecting improved economic forecasts.

Nonperforming assets, which includes nonaccrual loans and other real estate owned (the Bank had no other real estate owned during the periods reported), were $41.6 million as of March 31, 2026, $45.9 million as of December 31, 2025 and $49.9 million as of March 31, 2025. Nonperforming assets as a percentage of total assets improved to 0.29% as of March 31, 2026, versus 0.33% as of December 31, 2025 and 0.51% as of March 31, 2025. The ratio of nonaccrual loans to loans receivable also improved to 0.35%, as of March 31, 2026, versus 0.40% and 0.61%, at December 31, 2025 and March 31, 2025, respectively. The annualized net loan charge-offs ratio (excluding PCD loans) was 0.08% for the first quarter of 2026, 0.17% for the fourth quarter of 2025 and 0.17% for the first quarter of 2025.

The allowance for credit losses (“ACL”) represented 1.30%, 1.35% and 1.00% of loans receivable as of March 31, 2026, December 31, 2025 and March 31, 2025, respectively. The ACL decreased $1.2 million to $153.1 million as of March 31, 2026, compared to $154.3 million as of December 31, 2025. The ACL as a percentage of nonaccrual loans was 368.1% as of March 31, 2026, 336.1% as of December 31, 2025 and 165.3% as of March 31, 2025. 

Criticized and classified loans as a percentage of loans receivable improved to 2.26% as of March 31, 2026, down from 2.49% as of December 31, 2025 and from 2.79% as of March 31, 2025. Loans past due 30-59 days were 0.81% of loans receivable as of March 31, 2026, 0.19% as of December 31, 2025 and 0.18% as of March 31, 2025. This rise is predominantly due to an interrelated series of credits totaling $63.8 million secured by 19 multifamily NYC rent-regulated properties. We are working with our client to resolve these credits; however, the resulting financial impact cannot be determined at this time.

The Bank maintains a solid reserve position, particularly within its rent-regulated multifamily portfolio, which includes significant credit and fair value marks applicable to the portfolio acquired from FLIC, in addition to qualitative ACL allocations applicable to its legacy portfolio. The following table provides additional information on the Bank’s New York City (“NYC”) rent-regulated portfolio as of March 31, 2026:

($millions)   Portfolio

Composition
    % of Total
Loans
    Unpaid
Principal
Balance
    Offsets

(3)
    Offset %     Avg. Loan
Size
 
Acquired Portfolio (1)     61.0 %     3.5 %   $ 412.5     $ (66.1 )     16.0 %   $ 2.4  
Legacy ConnectOne (2)     39.0       2.2       263.4       (14.8 )     5.6       2.9  
Total Rent-Regulated     100.0 %     5.7 %   $ 675.9     $ (80.9 )     12.0       2.6  

   
Note: Rent-regulated includes loans secured by multifamily properties with 50% or greater units subject to NYC rent-stabilization guidelines.
(1) Portfolio acquired in merger with FLIC on June 1, 2025.
(2) Loans originated by the Bank.
(3) Offsets include (i) general reserves plus (ii) for the Acquired Portfolio, the applicable nonaccretable and accretable purchase accounting loan marks and (iii) for Legacy ConnectOne, an additional qualitative reserve applicable to rent-regulated multifamily.



Selected Balance Sheet Items

The Company’s total assets were $14.2 billion as of March 31, 2026, compared to $14.0 billion as of December 31, 2025. Loans receivable were $11.7 billion as of March 31, 2026 and $11.5 billion as of December 31, 2025. Total deposits were $11.5 billion as of March 31, 2026 and $11.2 billion as of December 31, 2025.

The Company’s total stockholders’ equity increased to $1.592 billion as of March 31, 2026 from $1.573 billion as of December 31, 2025. Retained earnings increased $27.3 million, partially offset by an increase in the accumulated other comprehensive loss of $6.2 million. As of March 31, 2026, the Company’s tangible common equity ratio and tangible book value per share were 8.64% and $23.93, respectively, compared to 8.62% and $23.52, respectively, as of December 31, 2025. Total goodwill and other intangible assets were $277.3 million as of March 31, 2026, and $280.2 million as of December 31, 2025.

Share Repurchase Program

During the first quarter of 2026, the Company repurchased 90,000 shares of common stock at an average price of $26.21, leaving 551,118 shares authorized for repurchase under the current Board approved repurchase program. The Company may repurchase shares from time to time in the open market, in privately negotiated stock purchases or pursuant to any trading plan that may be adopted in accordance with Rule 10b5-1 of the Securities and Exchange Commission and applicable federal securities laws. The share repurchase plan does not obligate the Company to acquire any particular amount of common stock and the plan may be modified or suspended at any time at the Company’s discretion.

Use of Non-GAAP Financial Measures

In addition to the results presented in accordance with Generally Accepted Accounting Principles (“GAAP”), ConnectOne routinely supplements its evaluation with an analysis of certain non-GAAP measures. ConnectOne believes these non-GAAP financial measures, in addition to the related GAAP measures, provide meaningful information to investors in understanding our operating performance and trends. These non-GAAP measures have inherent limitations and are not required to be uniformly applied and are not audited. They should not be considered in isolation or as a substitute for an analysis of results reported under GAAP. These non-GAAP measures may not be comparable to similarly titled measures reported by other companies. Reconciliations of non-GAAP financial measures disclosed in this earnings release to the comparable GAAP measures are provided in the accompanying tables.

First Quarter 2026 Results Conference Call

Management will also host a conference call and audio webcast at 10:00 a.m. ET on April 23, 2026, to review the Company’s financial performance and operating results. The conference call dial-in number is 1 (646) 307-1963, access code 8368502. Please dial in at least five minutes before the start of the call to register. An audio webcast of the conference call will be available to the public, on a listen-only basis, via the “Investor Relations” link on the Company’s website https://www.ConnectOneBank.com or at http://ir.connectonebank.com.

A replay of the conference call will be available beginning at approximately 1:00 p.m. ET on Thursday, April 23, 2026 and ending on Thursday, April 30, 2026, by dialing 1 (609) 800-9909, access code 8368502. An online archive of the webcast will be available following the completion of the conference call at https://www.ConnectOneBank.com or at http://ir.connectonebank.com.

About ConnectOne Bancorp, Inc.

ConnectOne Bancorp, Inc., is a modern financial services company that operates, through its subsidiary, ConnectOne Bank, and the Bank’s fintech subsidiary, BoeFly, Inc. ConnectOne Bank is a high-performing commercial bank offering a full suite of banking & lending products and services that focus on small to middle-market businesses. BoeFly, Inc. is a fintech marketplace that connects borrowers in the franchise space with funding solutions through a network of partner banks. ConnectOne Bancorp, Inc. is traded on the Nasdaq Global Market under the trading symbol “CNOB,” and information about ConnectOne may be found at https://www.connectonebank.com.

This news release contains certain forward-looking statements which are based on certain assumptions and describe future plans, strategies, and expectations of the Company. These forward-looking statements are generally identified by use of the words “believe,” “expect,” “intend,” “anticipate,” “estimate,” “project,” or similar expressions. The Company’s ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on the operations of the Company and its subsidiaries include, but are not limited to, those factors set forth in Item 1A  Risk Factors of the Companys Annual Report on Form 10-K, as filed with the U.S. Securities and Exchange Commission, as supplemented by the Companys subsequent filings with the U.S. Securities and Exchange Commission, and changes in interest rates, general economic conditions, legislative/regulatory changes, monetary and fiscal policies of the U.S. Government, including policies of the U.S. Treasury and the Federal Reserve Board, the quality or composition of the loan or investment portfolios, demand for loan products, deposit flows, competition, demand for financial services in the Company’s market area, changes in accounting principles and guidelines and the impact of the health emergencies and natural disasters on the Company, its employees and operations, and its customers. These risks and uncertainties should be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. The Company does not undertake, and specifically disclaims any obligation, to publicly release the result of any revisions which may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events. 


Investor Contact

:

William S. Burns

Senior Executive Vice President & CFO

201.816.4474;


[email protected]


Media Contact

:

Shannan Weeks 
MikeWorldWide
732.299.7890; [email protected]

C
ONNECT
O
NE
B
ANCORP,
I
NC. AND
S
UBSIDIARIES
         
CONSOLIDATED CONDENSED STATEMENTS OF FINANCIAL CONDITION        
(in thousands)          
  March 31,   December 31,   March 31,
    2026       2025       2025  
  (unaudited)       (unaudited)
ASSETS          
Cash and due from banks $ 39,472     $ 92,406     $ 49,759  
Interest-bearing deposits with banks   304,999       288,489       242,844  
Cash and cash equivalents   344,471       380,895       292,603  
           
Investment securities   1,196,384       1,250,938       636,806  
Equity securities   19,422       19,287       18,859  
           
Loans held-for-sale   10,222       391       202  
           
Loans receivable   11,735,596       11,453,280       8,201,134  
Less: Allowance for credit losses – loans   153,056       154,305       82,403  
Net loans receivable   11,582,540       11,298,975       8,118,731  
           
Investment in restricted stock, at cost   51,464       54,722       37,031  
Bank premises and equipment, net   54,765       55,285       27,624  
Accrued interest receivable   62,473       60,761       46,740  
Bank owned life insurance   373,664       370,713       244,651  
Right of use operating lease assets   27,960       29,603       13,755  
Goodwill   220,235       220,235       208,372  
Core deposit intangibles   57,078       59,923       4,360  
Other assets   208,883       200,972       109,521  
Total assets $ 14,209,561     $ 14,002,700     $ 9,759,255  
           
LIABILITIES          
Deposits:          
Noninterest-bearing $ 2,393,938     $ 2,420,397     $ 1,319,196  
Interest-bearing   9,119,115       8,820,218       6,448,034  
Total deposits   11,513,053       11,240,615       7,767,230  
Borrowings   827,477       903,489       613,053  
Subordinated debentures, net   202,050       201,864       80,071  
Operating lease liabilities   30,560       32,446       14,737  
Other liabilities   44,874       50,946       31,225  
Total liabilities   12,618,014       12,429,360       8,506,316  
           
COMMITMENTS AND CONTINGENCIES          
           
STOCKHOLDERS’ EQUITY          
Preferred stock   110,927       110,927       110,927  
Common stock   857,765       857,765       586,946  
Additional paid-in capital   38,257       38,763       36,007  
Retained earnings   701,154       673,897       643,265  
Treasury stock   (78,507 )     (76,116 )     (76,116 )
Accumulated other comprehensive loss   (38,049 )     (31,896 )     (48,090 )
Total stockholders’ equity   1,591,547       1,573,340       1,252,939  
Total liabilities and stockholders’ equity $ 14,209,561     $ 14,002,700     $ 9,759,255  
           

CONNECTONE BANCORP, INC. AND SUBSIDIARIES            
CONSOLIDATED STATEMENTS OF INCOME            
(dollars in thousands, except for per share data)            
  Three Months Ended
  03/31/26   12/31/25   03/31/25  
Interest income            
Interest and fees on loans $ 168,298   $ 167,532     $ 115,351  
Interest and dividends on investment securities:            
Taxable   10,799     11,628       4,987  
Tax-exempt   1,978     1,995       1,097  
Dividends   935     936       889  
Interest on federal funds sold and other short-term investments   2,387     4,249       2,465  
Total interest income   184,397     186,340       124,789  
Interest expense            
Deposits   65,682     70,854       53,992  
Borrowings   9,911     8,891       5,041  
Total interest expense   75,593     79,745       59,033  
             
Net interest income   108,804     106,595       65,756  
Provision for credit losses   5,200     2,300       3,500  
Net interest income after provision for credit losses   103,604     104,295       62,256  
             
Noninterest income            
Deposit, loan and other income   3,283     3,289       2,006  
Income on bank owned life insurance   2,951     2,946       1,584  
Net gains on sale of loans held-for-sale   427     631       332  
Net gains (losses) on equity securities   135     (846 )     529  
Total noninterest income   6,796     6,020       4,451  
             
Noninterest expenses            
Salaries and employee benefits   32,768     31,211       22,578  
Occupancy and equipment   5,345     5,265       2,680  
FDIC insurance   2,000     2,400       1,800  
Professional and consulting   3,108     2,908       2,366  
Marketing and advertising   926     974       595  
Information technology and communications   5,243     5,366       4,604  
Merger expenses and restructuring charges   2,125     498       1,320  
Branch closing expenses       1,275        
Bank owned life insurance restructuring charge             327  
Amortization of core deposit intangibles   2,845     3,196       279  
Other expenses   3,509     3,853       2,756  
Total noninterest expenses   57,869     56,946       39,305  
             
Income before income tax expense   52,531     53,369       27,402  
Income tax expense   14,709     13,851       7,160  
Net income   37,822     39,518       20,242  
Preferred dividends   1,509     1,509       1,509  
Net income available to common stockholders $ 36,313   $ 38,009     $ 18,733  
             
Earnings per common share:            
Basic $ 0.72   $ 0.76     $ 0.49  
Diluted   0.72     0.75       0.49  
             

ConnectOne’s management believes that the supplemental financial information, including non-GAAP measures provided below, is useful to investors. The non-GAAP measures should not be viewed as a substitute for financial results determined in accordance with GAAP, and are not necessarily comparable to non-GAAP financial measures presented by other companies.  
                     
CONNECTONE BANCORP, INC.                    
SUPPLEMENTAL GAAP AND NON-GAAP FINANCIAL MEASURES                    
  As of  
  Mar. 31,   Dec. 31,   Sept. 30,   Jun. 30,   Mar. 31,  
    2026       2025       2025       2025       2025    

Selected Financial Data
(dollars in thousands)  
Total assets $ 14,209,561     $ 14,002,700     $ 14,023,585     $ 13,915,738     $ 9,759,255    
Loans receivable:                    
Commercial   1,638,836       1,558,436       1,613,421       1,597,590       1,483,392    
Commercial real estate   4,750,508       4,625,143       4,310,159       4,285,663       3,356,943    
Multifamily   3,574,336       3,437,080       3,420,465       3,348,308       2,490,256    
Commercial construction   571,073       623,902       728,615       681,222       617,593    
Residential   1,202,539       1,210,980       1,233,305       1,254,646       256,555    
Consumer   1,801       2,017       2,166       1,709       1,604    
Gross loans   11,739,093       11,457,558       11,308,131       11,169,138       8,206,343    
Net deferred loan fees   (3,497 )     (4,278 )     (4,495 )     (4,661 )     (5,209 )  
Loans receivable   11,735,596       11,453,280       11,303,636       11,164,477       8,201,134    
Loans held-for-sale   10,222       391             1,027       202    
Total loans $ 11,745,818     $ 11,453,671     $ 11,303,636     $ 11,165,504     $ 8,201,336    
                     
Investment and equity securities $ 1,215,806     $ 1,270,225     $ 1,272,335     $ 1,246,907     $ 655,665    
Goodwill and other intangible assets   277,313       280,158       278,730       281,926       212,732    
Deposits:                    
Noninterest-bearing demand $ 2,393,938     $ 2,420,397     $ 2,513,102     $ 2,424,529     $ 1,319,196    
Time deposits   3,010,971       2,796,877       2,977,952       3,065,015       2,550,223    
Other interest-bearing deposits   6,108,144       6,023,341       5,878,241       5,788,943       3,897,811    
Total deposits $ 11,513,053     $ 11,240,615     $ 11,369,295     $ 11,278,487     $ 7,767,230    
                     
Borrowings $ 827,477     $ 903,489     $ 833,443     $ 783,859     $ 613,053    
Subordinated debentures (net of debt issuance costs)   202,050       201,864       201,677       276,500       80,071    
Total stockholders’ equity   1,591,547       1,573,340       1,538,344       1,496,431       1,252,939    
                     

Quarterly Average Balances
                   
Total assets $ 13,999,581     $ 13,963,138     $ 14,050,585     $ 11,108,430     $ 9,748,605    
Loans receivable:                    
Commercial $ 1,579,368     $ 1,597,123     $ 1,583,673     $ 1,486,245     $ 1,488,962    
Commercial real estate (including multifamily)   8,137,515       7,822,943       7,630,195       6,404,302       5,852,342    
Commercial construction   613,661       646,414       704,170       643,115       610,859    
Residential   1,204,082       1,221,171       1,241,375       587,118       256,430    
Consumer   6,851       5,473       6,747       5,759       5,687    
Gross loans   11,541,477       11,293,124       11,166,160       9,126,539       8,214,280    
Net deferred loan fees   (4,042 )     (4,708 )     (4,418 )     (5,097 )     (5,525 )  
Loans receivable   11,537,435       11,288,416       11,161,742       9,121,442       8,208,755    
Loans held-for-sale   335       230       318       352       259    
Total loans $ 11,537,770     $ 11,288,646     $ 11,162,060     $ 9,121,794     $ 8,209,014    
                     
Investment and equity securities $ 1,256,147     $ 1,269,275     $ 1,274,000     $ 845,614     $ 655,191    
Goodwill and other intangible assets   279,158       279,165       280,814       235,848       212,915    
Deposits:                    
Noninterest-bearing demand   2,384,883       2,473,596       2,486,993       1,680,653       1,305,722    
Time deposits   2,901,327       2,946,459       3,019,848       2,662,411       2,480,990    
Other interest-bearing deposits   5,996,487       5,907,547       5,889,230       4,463,648       3,888,131    
Total deposits $ 11,282,697     $ 11,327,602     $ 11,396,071     $ 8,806,712     $ 7,674,843    
                     
Borrowings $ 833,551     $ 781,388     $ 783,994     $ 723,303     $ 686,391    
Subordinated debentures (net of debt issuance costs)   201,928       201,741       263,511       170,802       79,988    
Total stockholders’ equity   1,594,699       1,558,366       1,513,892       1,344,254       1,254,373    
                     
  Three Months Ended  
  Mar. 31,   Dec. 31,   Sept. 30,   Jun. 30,   Mar. 31,  
    2026       2025       2025       2025       2025    
  (dollars in thousands, except for per share data)  
Net interest income $ 108,804     $ 106,595     $ 102,017     $ 78,883     $ 65,756    
Provision for credit losses   5,200       2,300       5,500       35,700       3,500    
Net interest income after provision for credit losses   103,604       104,295       96,517       43,183       62,256    
Noninterest income                    
Deposit, loan and other income   3,283       3,289       3,836       2,570       2,006    
Defined benefit pension plan curtailment gain               3,501                
Employee retention tax credit               6,608                
Income on bank owned life insurance   2,951       2,946       2,931       2,087       1,584    
Net gains on sale of loans held-for-sale   427       631       859       181       332    
Net gains (losses) on equity securities   135       (846 )     1,674       347       529    
Total noninterest income   6,796       6,020       19,409       5,185       4,451    
Noninterest expenses                    
Salaries and employee benefits   32,768       31,211       32,401       25,233       22,578    
Occupancy and equipment   5,345       5,265       5,122       3,478       2,680    
FDIC insurance   2,000       2,400       2,400       2,000       1,800    
Professional and consulting   3,108       2,908       2,929       2,598       2,366    
Marketing and advertising   926       974       771       840       595    
Information technology and communications   5,243       5,366       5,243       4,792       4,604    
Restructuring and exit charges               994                
Merger expenses and restructuring charges   2,125       498       1,898       30,745       1,320    
Branch closing expenses         1,275                      
Bank owned life insurance restructuring charge                           327    
Amortization of core deposit intangible   2,845       3,196       3,196       1,251       279    
Other expenses   3,509       3,853       3,719       2,712       2,756    
Total noninterest expenses   57,869       56,946       58,673       73,649       39,305    
                     
Income (loss) before income tax expense   52,531       53,369       57,253       (25,281 )     27,402    
Income tax expense (benefit)   14,709       13,851       16,277       (4,988 )     7,160    
Net income (loss)   37,822       39,518       40,976       (20,293 )     20,242    
Preferred dividends   1,509       1,509       1,509       1,509       1,509    
Net income (loss) available to common stockholders $ 36,313     $ 38,009     $ 39,467     $ (21,802 )   $ 18,733    
                     
Weighted average diluted common shares outstanding   50,382,297       50,414,115       50,462,030       42,173,758       38,511,237    
Diluted EPS $ 0.72     $ 0.75     $ 0.78     $ (0.52 )   $ 0.49    
                     

Reconciliation of GAAP Net Income to Operating Net Income:
                   
Net income (loss) $ 37,822     $ 39,518     $ 40,976     $ (20,293 )   $ 20,242    
Restructuring and exit charges               994                
Merger expenses and restructuring charges   2,125       498       1,898       30,745       1,320    
Estimated state tax liability on intercompany dividends                     3,000          
Initial provision for credit losses related to merger                     27,418          
Branch closing expenses         1,275                      
Bank owned life insurance restructuring charge                           327    
Amortization of core deposit intangibles   2,845       3,196       3,196       1,251       279    
Net (gains) losses on equity securities   (135 )     846       (1,674 )     (347 )     (529 )  
Defined benefit pension plan curtailment gain               (3,501 )              
Employee retention tax credit               (6,608 )              
Tax impact of adjustments   (1,499 )     (1,802 )     1,737       (17,168 )     (420 )  
Operating net income $ 41,158     $ 43,531     $ 37,018     $ 24,606     $ 21,219    
Preferred dividends   1,509       1,509       1,509       1,509       1,509    
Operating net income available to common stockholders $ 39,649     $ 42,022     $ 35,509     $ 23,097     $ 19,710    
                     
Operating diluted EPS (non-GAAP) (1) $ 0.79     $ 0.83     $ 0.70     $ 0.55     $ 0.51    
                     

Return on Assets Measures
                   
Average assets $ 13,999,581     $ 13,963,138     $ 14,050,585     $ 11,108,430     $ 9,748,605    
Return on avg. assets   1.10   %   1.12   %   1.16   %   (0.73 ) %   0.84   %
Operating return on avg. assets (non-GAAP) (2)   1.19       1.24       1.05       0.89       0.88    
Pre-provision net operating revenue (“PPNR”) return on avg. assets (non-GAAP) (3)   1.81       1.75       1.61       1.52       1.34    
                     
(1) Operating net income available to common stockholders divided by weighted average diluted shares outstanding.
(2) Operating net income divided by average assets.
(3) Net income before income tax expense, provision for credit losses, merger expenses and restructuring charges, branch closing expenses, BOLI restructuring charges, restructuring and exit charges, employee retention tax credit, defined benefit pension plan curtailment gain, amortization of core deposit intangibles and net gains on equity securities divided by average assets.
 
                     
  Three Months Ended  
  Mar. 31,   Dec. 31,   Sept. 30,   Jun. 30,   Mar. 31,  
    2026       2025       2025       2025       2025    

Return on Equity Measures
(dollars in thousands)  
Average stockholders’ equity $ 1,594,699     $ 1,558,366     $ 1,513,892     $ 1,344,254     $ 1,254,373    
Less: average preferred stock   (110,927 )     (110,927 )     (110,927 )     (110,927 )     (110,927 )  
Average common equity $ 1,483,772     $ 1,447,439     $ 1,402,965     $ 1,233,327     $ 1,143,446    
Less: average intangible assets   (279,158 )     (279,165 )     (280,814 )     (235,848 )     (212,915 )  
Average tangible common equity $ 1,204,614     $ 1,168,274     $ 1,122,151     $ 997,479     $ 930,531    
Return on avg. common equity (GAAP)   9.93   %   10.42   %   11.16   %   (7.09 ) %   6.64   %
Operating return on avg. common equity (non-GAAP) (4)   10.84       11.52       10.04       7.51       6.99    
Return on avg. tangible common equity (non-GAAP) (5)   12.89       13.66       14.74       (8.42 )     8.25    
Operating return on avg. tangible common equity (non-GAAP) (6)   13.35       14.27       12.55       9.29       8.59    
                     

Efficiency Measures
                   
Total noninterest expenses $ 57,869     $ 56,946     $ 58,673     $ 73,649     $ 39,305    
Restructuring and exit charges               (994 )              
Merger expenses and restructuring charges   (2,125 )     (498 )     (1,898 )     (30,745 )     (1,320 )  
Branch closing expenses         (1,275 )                    
Bank owned life insurance restructuring charge                           (327 )  
Amortization of core deposit intangibles   (2,845 )     (3,196 )     (3,196 )     (1,251 )     (279 )  
Operating noninterest expense $ 52,899     $ 51,977     $ 52,585     $ 41,653     $ 37,379    
                     
Net interest income (tax equivalent basis) $ 109,976     $ 107,761     $ 103,155     $ 79,810     $ 66,580    
Noninterest income   6,796       6,020       19,409       5,185       4,451    
Defined benefit pension plan curtailment gain               (3,501 )              
Employee retention tax credit               (6,608 )              
Net (gains) losses on equity securities   (135 )     846       (1,674 )     (347 )     (529 )  
Operating revenue $ 116,637     $ 114,627     $ 110,781     $ 84,648     $ 70,502    
                     
Operating efficiency ratio (non-GAAP) (7)   45.4   %   45.3   %   47.5   %   49.2   %   53.0   %
                     

Net Interest Margin
                   
Average interest-earning assets $ 13,160,794     $ 13,093,053     $ 13,172,443     $ 10,468,589     $ 9,224,712    
Net interest income (tax equivalent basis) $ 109,976     $ 107,761     $ 103,155     $ 79,810     $ 66,580    
Net interest margin (non-GAAP)   3.39   %   3.27   %   3.11   %   3.06   %   2.93   %
                     
(4) Operating net income available to common stockholders divided by average common equity.
(5) Net income available to common stockholders, excluding amortization of intangible assets, divided by average tangible common equity.
(6) Operating net income available to common stockholders, divided by average tangible common equity.
(7) Operating noninterest expense divided by operating revenue.
                     
  As of  
  Mar. 31,   Dec. 31,   Sept. 30,   Jun. 30,   Mar. 31,  
    2026       2025       2025       2025       2025    

Capital Ratios and Book Value per Share
(dollars in thousands, except for per share data)  
Stockholders equity $ 1,591,547     $ 1,573,340     $ 1,538,344     $ 1,496,431     $ 1,252,939    
Less: preferred stock   (110,927 )     (110,927 )     (110,927 )     (110,927 )     (110,927 )  
Common equity $ 1,480,620     $ 1,462,413     $ 1,427,417     $ 1,385,504     $ 1,142,012    
Less: intangible assets   (277,313 )     (280,158 )     (278,730 )     (281,926 )     (212,732 )  
Tangible common equity $ 1,203,307     $ 1,182,255     $ 1,148,687     $ 1,103,578     $ 929,280    
                     
Total assets $ 14,209,561     $ 14,002,700     $ 14,023,585     $ 13,915,738     $ 9,759,255    
Less: intangible assets   (277,313 )     (280,158 )     (278,730 )     (281,926 )     (212,732 )  
Tangible assets $ 13,932,248     $ 13,722,542     $ 13,744,855     $ 13,633,812     $ 9,546,523    
                     
Common shares outstanding   50,288,494       50,271,854       50,273,089       50,270,162       38,469,975    
                     
Common equity ratio (GAAP)   10.42   %   10.44   %   10.18   %   9.96   %   11.70   %
Tangible common equity ratio (non-GAAP) (8)   8.64       8.62       8.36       8.09       9.73    
                     
Regulatory capital ratios (Bancorp):                    
Leverage ratio   9.79   %   9.61   %   9.35   %   11.58   %   11.33   %
Common equity Tier 1 risk-based ratio   10.23       10.24       10.17       10.04       11.14    
Risk-based Tier 1 capital ratio   11.19       11.22       11.17       11.06       12.46    
Risk-based total capital ratio   13.81       13.88       13.88       14.35       14.29    
                     
Regulatory capital ratios (Bank):                    
Leverage ratio   10.81   %   10.59   %   10.35   %   12.81   %   11.67   %
Common equity Tier 1 risk-based ratio   12.36       12.36       12.37       12.22       12.82    
Risk-based Tier 1 capital ratio   12.36       12.36       12.37       12.22       12.82    
Risk-based total capital ratio   13.34       13.33       13.38       13.24       13.79    
                     
Book value per share (GAAP) $ 29.44     $ 29.09     $ 28.39     $ 27.56     $ 29.69    
Tangible book value per share (non-GAAP) (9)   23.93       23.52       22.85       21.95       24.16    
                     
(8) Tangible common equity divided by tangible assets
(9) Tangible common equity divided by common shares outstanding at period-end
                     
  As of  
  Mar. 31,   Dec. 31,   Sept. 30,   Jun. 30,   Mar. 31,  
    2026       2025       2025       2025       2025    

Net Loan Charge-offs (Recoveries) (10):
(dollars in thousands)  
Net loan charge-offs (recoveries):                    
Charge-offs $ 2,758     $ 5,613     $ 5,174     $ 5,039     $ 3,555    
Recoveries   (467 )     (836 )     (38 )     (118 )     (155 )  
Net loan charge-offs $ 2,291     $ 4,777     $ 5,136     $ 4,921     $ 3,400    
Net loan charge-offs as a % of average loans receivable (annualized)   0.08   %   0.17   %   0.18   %   0.22   %   0.17   %
                     
(10) Includes only non-PCD loans
                     
                     
  As of  
  Mar. 31,   Dec. 31,   Sept. 30,   Jun. 30,   Mar. 31,  
    2026       2025       2025       2025       2025    

Asset Quality
(dollars in thousands)  
Nonaccrual loans $ 41,579     $ 45,915     $ 39,671     $ 39,228     $ 49,860    
Other real estate owned                              
Nonperforming assets $ 41,579     $ 45,915     $ 39,671     $ 39,228     $ 49,860    
                     
Allowance for credit losses – loans (excluding nonaccretable credit marks) $ 115,398     $ 112,282     $ 113,163     $ 112,854     $ 82,230    
Add: nonaccretable credit marks   37,658       42,023       43,336       43,336       173    
Allowance for credit losses – loans (“ACL”) $ 153,056     $ 154,305     $ 156,499     $ 156,190     $ 82,403    
                     
Loans receivable $ 11,735,596     $ 11,453,280     $ 11,303,636     $ 11,164,477     $ 8,201,134    
                     
Nonaccrual loans as a % of loans receivable   0.35   %   0.40   %   0.35   %   0.35   %   0.61   %
Nonperforming assets as a % of total assets   0.29       0.33       0.28       0.28       0.51    
ACL as a % of loans receivable   1.30       1.35       1.38       1.40       1.00    
ACL as a % of nonaccrual loans   368.1       336.1       394.5       398.2       165.3    
                     

CONNECTONE BANCORP, INC.                                        
NET INTEREST MARGIN ANALYSIS                                        
(dollars in thousands)                                        
  For the Three Months Ended  
  March 31, 2026 December 31, 2025 March 31, 2025
  Average             Average             Average          
Interest-earning assets: Balance   Interest   Rate
(7)
    Balance   Interest   Rate
(7)
    Balance   Interest   Rate
(7)
 
Investment securities (1) (2) $ 1,307,184     $ 13,302     4.13 %   $ 1,329,393     $ 14,154     4.22 %   $ 745,873     $ 6,375     3.47 %
Loans receivable and loans held-for-sale (2) (3) (4)   11,537,770       168,945     5.94       11,288,646       168,167     5.91       8,209,014       115,883     5.73  
Federal funds sold and interest-                                        
bearing deposits with banks   264,232       2,387     3.66       425,840       4,249     3.96       229,491       2,466     4.36  
Restricted investment in bank stock   51,608       935     7.35       49,174       936     7.55       40,334       889     8.94  
Total interest-earning assets   13,160,794       185,569     5.72       13,093,053       187,506     5.68       9,224,712       125,613     5.52  
Allowance for loan losses   (154,481 )               (158,576 )               (84,027 )          
Noninterest-earning assets   993,268                 1,028,661                 607,920            
Total assets $ 13,999,581               $ 13,963,138               $ 9,748,605            
                                         
Interest-bearing liabilities:                                        
 Money market deposits   2,903,419       20,146     2.81       2,919,230       21,882     2.97       1,572,287       11,287     2.91  
 Savings deposits   1,014,568       6,304     2.52       1,012,567       7,233     2.83       656,789       5,227     3.23  
 Time deposits   2,901,327       26,713     3.73       2,946,459       28,520     3.84       2,480,990       25,154     4.11  
 Other interest-bearing deposits   2,078,500       12,519     2.44       1,975,750       13,219     2.65       1,659,055       12,324     3.01  
Total interest-bearing deposits   8,897,814       65,682     2.99       8,854,006       70,854     3.17       6,369,121       53,992     3.44  
                                         
Borrowings   833,551       5,513     2.68       781,388       4,582     2.33       686,391       3,725     2.20  
Subordinated debentures   201,928       4,385     8.81       201,741       4,294     8.44       79,988       1,298     6.58  
Finance lease   921       13     5.72       995       15     5.98       1,210       18     6.03  
Total interest-bearing liabilities   9,934,214       75,593     3.09       9,838,130       79,745     3.22       7,136,710       59,033     3.35  
                                         
Noninterest-bearing demand deposits   2,384,883                 2,473,596                 1,305,722            
Other liabilities   85,785                 93,046                 51,800            
Total noninterest-bearing liabilities   2,470,668                 2,566,642                 1,357,522            
Stockholders’ equity   1,594,699                 1,558,366                 1,254,373            
Total liabilities and stockholders’ equity $ 13,999,581               $ 13,963,138               $ 9,748,605            
                                         
Net interest income (tax equivalent basis)       109,976                 107,761                 66,580        
Net interest spread (5)         2.63 %           2.46 %           2.17 %
                                         
Net interest margin (6)         3.39 %           3.27 %           2.93 %
                                         
Tax equivalent adjustment       (1,172 )               (1,166 )               (824 )      
Net interest income     $ 108,804               $ 106,595               $ 65,756        
                                         
(1) Average balances are calculated on amortized cost.
(2) Interest income is presented on a tax equivalent basis using 21% federal tax rate.
(3) Includes loan fee income.
(4) Loans include nonaccrual loans.
(5) Represents difference between the average yield on interest-earning assets and the average cost of interest-bearing
liabilities and is presented on a tax equivalent basis.
(6) Represents net interest income on a tax equivalent basis divided by average total interest-earning assets.
(7) Rates are annualized.